UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended March 31, 20122014
 
OR
 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number 000-28827
Commission File Number 000-28827

PETMED EXPRESS, INC.
(Exact name of registrant as specified in its charter)
FLORIDA65-0680967
(State or other jurisdiction of(IRS Employer
incorporation or organization)Identification No.)
  
1441 S.W. 29th Avenue, Pompano Beach, Florida 33069
(Address of principal executive offices) (Zip Code)
 
       Registrant’s telephone number, including area code: (954) 979-5995
 
     Securities registered under Section 12(b) of the Act:
 
Title of each class
Name of each exchange on which
registered
  
COMMON  STOCK,  $.001  PAR  VALUE
The NASDAQ Stock Market LLC
(NASDAQ Global Select Market)
 
Securities registered under Section 12(g) of the Act:
 
NONE

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405232.405 of this chapter) during the preceeding12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter)  is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of “accelerated filer”, “large accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):
 
Large accelerated fileroAccelerated filerx
 Non-accelerated fileroSmaller reporting companyo
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No x
 
The aggregate market value of the registrant’s common stockCommon Stock held by non-affiliates of the registrant as of September 30, 2011,2013, the last business day of the registrant’s most recently completed second fiscal quarter, was $177.0$312.2 million based on the closing sales price of the registrant’s Common Stock on that date, as reported on the NASDAQ Global Select Market.
 
The number of shares of the registrant’s Common Stock outstanding as of May 28, 201227, 2014 was 20,334,941.20,189,440.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Information to be set forth in our Proxy Statement relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 201225, 2014 is incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this report.
 



 
PETMED EXPRESS, INC.
 
20122014 Annual Report on Form 10-K
 
TABLE OF CONTENTS

   
Page
PART I
1
Item 1.
Business
1
Item 1A.
Risk Factors
6
Item 1B.
Unresolved Staff Comments
11
Item 2.
Properties
11
Item 3.
Legal Proceedings
11
Item 4.
Mine Safety Disclosures
11
    
PART I  1
PART II
Item 1.
Business1
Item 1A.Risk Factors6
Item 1B.Unresolved Staff Comments11
Item 2.Properties11
Item 3.Legal Proceedings11
Item 4.Mine Safety Disclosures11
   
12
Item 5.
PART II
 
12
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 
12
Item 6.
Selected Financial Data 
Selected Financial Data
15
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
16
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
 
23
22
Item 8.
Financial Statements and Supplementary Data
 
24
23
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial  Disclosure
 
44
41
Item 9A.
Controls and Procedures 
Controls and Procedures
41
Item 9B.Other Information 
44
Item 9B.
Other Information
44
41
    
PART III
  
45
42
Item 10.
Directors, Executive Officers, and Corporate Governance
 
45
42
Item 11.
Executive Compensation 
Executive Compensation
45
42
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
45
42
Item 13.
Certain Relationships and Related Transactions, and Director Independence
 
45
42
Item 14.
Principal Accountant Fees and Services
 
45
42
    
PART IV
  
46
43
Item 15.
Exhibits, Financial Statement Schedules
 
46
43
   
SIGNATURES 
SIGNATURES
47
44
                

 
PART I
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
 
Certain information in this Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  You can identify these forward-looking statements by the words “believes,believes,” “intends,” “expects,” “may,” “will,” “should,” “plan,” “projects,” “contemplates,” “intends,” “budgets,” “predicts,” “estimates,” “anticipates, “intends,” “expects,” “may,” “will,” “should,” “plan,” “projects,” “contemplates,” “intends,” “budgets,” “predicts,” “estimates,” “anticipates,” or similar expressions.  These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us.  Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions.  Actual future results may differ significantly from the results discussed in the forward-looking statements.  A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Annual Report.
 
When used in this Annual Report on Form 10-K, PetMed Express,“1-800-PetMeds,1-800-PetMeds, “PetMeds,” “PetMed,PetMed, “PetMeds.com,” “PetMedPetMed Express.com,“thethe Company,”  “we,we,“our,our, and “us”us refer to PetMed Express, Inc. and our wholly-owned subsidiaries.
 
ITEM 1. BUSINESS
 
General
 
PetMed Express, Inc. and subsidiaries, d/b/a 1-800-PetMeds, is a leading nationwide pet pharmacy.  The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer.  The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, and speed of delivery.
 
The Company markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the “1-800-PetMeds” brand name, and “PetMeds” family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases.  Our fiscal year end is March 31, our executive offices are located at 1441 S.W. 29th Avenue, Pompano Beach, Florida 33069, and our telephone number is (954) 979-5995.
 
Our Products
 
We offer a broad selection of products for dogs and cats.  Our current product line contains approximately 1200 SKUS.3000 SKUS of the most popular pet medications, health products, and supplies.  These products include a majority of the well-known brands of medication, such as Frontline Plus®, K9 Advantix® II, Advantage® II, Heartgard Plus®, Sentinel®, Interceptor®, Program®, Revolution®, Deramaxx®, and Rimadyl®.  Generally, our prices are competitive with the prices for medications charged by veterinarians and retailers.  In March 2010, the Companywe started offering for sale additional pet supplies on our website, which are drop shipped to our customers by third parties.  These pet supplies include: food, beds, crates, stairs, strollers, and other popular pet supplies.
 
We research new products, and regularly select new products or the latest generation of existing products to become part of our product selection.  In addition, we also refine our current products to respond to changing consumer-purchasing habits.  Our website is designed to give us the flexibility to change featured products or promotions.  Our product line provides customers with a wide variety of selections across the most popular health categories for dogs and cats.  Our current products include:
 
Non-Prescription Medications (OTC) and supplies: Flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies.
 
Prescription Medications (Rx): Heartworm preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.
 
1

Sales
 
The following table provides a breakdown of the percentage of our total sales by each category during the indicated periods:
  Year Ended March 31, 
  2012  2011  2010 
 
Non-prescription medications and supplies
  59%  61%  64%
Prescription medications  40%  38%  35%
Shipping and handling charges and other  1%  1%  1%
Total  100%  100%  100%

  Year Ended March 31, 
  2014  2013  2012 
          
Non-prescription medications and supplies  55%  59%  59%
Prescription medications  44%  40%  40%
Shipping and handling charges and other  1%  1%  1%
Total  100%  100%  100%
We offer our products through three main sales channels: Internet through our website, telephone contact center through our toll-free number, and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards.  We have designed our catalogs and website to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet’s health and quality of life.  We believe that these multiple channels allow us to increase the visibility of our brand name and provide our customers with increased shopping flexibility and excellent service.
 
Internet
 
We seek to combine our product selection and pet health information with the shopping ease of the Internet to deliver a convenient and personalized shopping experience.  Our website offers health and nutritional product selections for dogs and cats, and relevant editorial and easily obtainable or retrievable resource information.  From our home page, customers can search our website for products and access resources on a variety of information on dogs and cats.  Customers can shop at our website by category, product line, individual product, or symptom.  We attracted approximately 19.127 million visitors to our website during fiscal 2012,2014, approximately 13%10% of those visitors placed an order, and our website generated approximately 75%79% of our total sales for the same time period.
In February 2006, we began sponsorship of a  On our website called “PetHealth101 which is located at www.PetHealth101.com.  In PetHealth101, pet owners have access to health information covering pets’ behavior and illnesses, and natural and pharmaceutical remedies specifically for a pet’s problems.  During fiscal 2012, the PetHealth101 content was incorporated into our main website.problem.  The pet education content on our main website is periodically updated with the latest research for pet owners.
 
Telephone Contact Center
 
Our customer care representatives receive and process inbound and outbound customer calls, facilitate our live web chat, and process customer e-mails.  Our telephone system is equipped with certain features including pop-up screens and call blending capabilities that give us the ability to efficiently utilize our customer care representatives’ time, providing excellent customer care, service, and support.  Our customer care representatives receive a base salary and are rewarded with commissions for sales, and bonuses and other awards for achieving certain quality goals.
 
Direct Mail/Print
 
The 1-800-PetMeds catalog is a full-color catalog that features our most popular products.  The catalog is produced by a combination of in-house writers, production artists, and independent contractors.  We mail catalogs, brochures, and postcards in response to requests generated from our advertising and as part of direct mail campaigns to our customers.
 
Our Customers
 
Approximately 2.72.6 million customers have purchased from us within the last two years.  We attracted approximately 722,000597,000 and 645,000630,000 new customers in fiscal 20122014 and 2011,2013, respectively.  Our customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey.  Our primary focus has been on retail customers and the average purchase was approximately $76$75 for fiscal 20122014 compared to $79$73 for fiscal 2011.
2

2013.
 
Marketing
 
The goal of our marketing strategy is to build brand recognition, increase customer traffic, add new customers, build strong customer loyalty, maximize reorders, and develop incremental revenue opportunities.  We have an integrated marketing campaign that includes television advertising, online marketing, direct mail/print and e-mail.
 
Television Advertising
 
Our television advertising is designed to build brand equity, create brand awareness, and generate initial purchases of products via the telephone and the Internet.  We have used :30 and :15 second television commercials to attract new customer orders.  Our television commercials typically focus on our ability to rapidly deliver to customers the same medications offered by veterinarians, but at reduced prices.  We generally purchase advertising on national cable channels to target our key demographic group – women, ages 30 to 65.  We believe that television advertising is particularly effective and instrumental in building brand awareness.
 
Online Marketing
 
We supplement our traditional advertising with online advertising and marketing efforts.  We make our brand available to Internet consumers by purchasing targeted keywords and achieving prominent placement on the top search engines and search engine networks, including Google, Bing™, and Yahoo®.  We utilize Internet display and video advertisements, social media, and comparison shopping, and we are also members of the LinkShare Network, which is an affiliate program with merchant clients and affiliate websites.
 
Direct Mail/Print and E-mail
 
We use direct mail/print and e-mail to acquire new customers and to remind our existing customers to reorder.
 
Operations
 
Order Processing
 
Our website allows customers to easily browse and purchase all of our products online.  Our website is designed to be fast, secure, and easy to use with order and shipping confirmations, and with online order tracking capabilities.  We provide our customers with toll-free telephone access to our customer care representatives.  Our call center generally operates from 8:00 AM to 11:00 PM, Monday through Thursday, 8:00 AM to 9:00 PM on Friday, 9:00 AM to 6:00 PM on Saturday, and 10:00 AM to 5:00 PM on Sunday, Eastern Time.  The process of customers purchasing products from 1-800-PetMeds consists of a few simple steps.  A customer first places a call to our toll-free telephone number or visits our website.  The following information is needed to process prescription orders: pet information, prescription information, and the veterinarian’s name and phone number.  This information is entered into our computer system.  Then our pharmacists and pharmacy technicians verify all prescriptions.  The order process system checks for the verification for prescription medication orders and a valid payment method for all orders.  An invoice is generated and printed in our fulfillment center, where items are picked, and then shipped via United States Postal Service, Federal Express, or UPS.  Our customers enjoy the convenience of rapid home delivery, with approximately 80%79% of all orders being shipped within 24 hours of ordering.
 
Customer Care and Support
 
We believe that a high level of customer care and support is critical in retaining and expanding our customer base.  Customer care representatives participate in ongoing training programs under the supervision of our training managers.  These training sessions include a variety of topics such as product knowledge, computer usage, customer service tips, and the relationship between our Company and veterinarians.  Our customer care representatives respond to customers’ e-mails, calls, and callslive chats that are related to products, order status, prices, and shipping.  Our customer care representatives also respond to customers through our live web chat.   We believe our customer care representatives are a valuable source of feedback regarding customer satisfaction.  Our customer returns and credits averaged approximately 1.5% of total sales for fiscal 2012.
3

 
Warehousing and Shipping
 
We inventory our products and fill most customer orders from our corporate headquarters in Pompano Beach, Florida.  We have an in-house fulfillment and distribution operation, which is used to manage the entire supply chain, beginning with the placement of the order, continuing through order processing, and then fulfilling and shipping of the product to the customer.  We offer a variety of shipping options, including next day delivery.  We ship to anywhere in the United States served by the United States Postal Service, Federal Express, or UPS.  Priority orders are expedited in our fulfillment process.  Our goal is to ship the products the same day that the order is received.  For prescription medications, our goal is to ship the product immediately after the prescription has been authorized by the customer’s veterinarian.
 
Purchasing
 
We purchase our products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers.  There were fourfive suppliers from whom we purchased approximately 50% of all products in fiscal 2012.2014.  We purchase the majority of ourthe health and nutritional supplements directly from manufacturers.  We believe having strong relationships with product manufacturers will ensure the availability of an adequate volume of products ordered by our customers, and will enable us to provide more and better product information.  Historically, substantially all the major manufacturers of prescription and non-prescription medications have declined to sell these products to direct marketing companies, such as our Company.  (See Risk Factors.)  Part of our growth strategy includes developing direct relationships with the leading pharmaceutical manufacturers of the more popular prescription and non-prescription medications.  In March 2010 Bayer started making their products available directly to pet specialty retailers and internet sites, including our Company.
 
Technology
 
We utilize integrated technologies in our call centers, e-commerce, order entry, and inventory control/fulfillment operations.  Our systems are custom configured by the Company to optimize our computer telephone integration and mail-order processing.  The systems are designed to maintain a large database of specialized information and process a large volume of orders efficiently and effectively.  Our systems provide our customer care representatives, and our customers on our website, with real time product availability information and updated customer information to enhance our customer care.  We also have an integrated direct connection for processing credit cards to ensure that a valid credit card number and authorization have been received at the same time our customer care representatives are on the phone with the customer or when a customer submits an order on our website.  Our information systems provide our customer care representatives with records of all prior contact with a customer, including the customer’s address, phone number, e-mail address, prescription information, order history, payment history, and notes.
 
Competition
 
The pet medications market is competitive and highly fragmented.  Our competitors consist of veterinarians, and online and traditional retailers.  We believe that the following are the principal competitive factors in our market:
 
 
Product selection and availability, including the availability of prescription and non-prescription medications;
 
Brand recognition;
 
Reliability and speed of delivery;
 
Personalized service and convenience;
 
Price; and
 
Quality of website content.
 
We compete with veterinarians for the sale of prescription and non-prescription pet medications and other health products.  Many pet owners may prefer the convenience of purchasing their pet medications or other health products at the time of a veterinarian visit, or may be hesitant to offend their veterinarian by not purchasing these products from the veterinarian.visit.  In order to effectively compete with veterinarians, we must continue to educate pet owners about the service, convenience, and savings offered by our Company.
 
4

According to the American Pet Products Manufacturers Association, pet spending in the United States increased 5.3%4.5% to $51.0$55.7 billion in 2011.2013.  Pet supplies and medications represented $11.8$13.1 billion, or 23%24% of the total spending on pets in the United States.  The pet medication market that we participate in is estimated to be approximately $4.0 billion, with veterinarians having the majority of the market share.  The dog and cat population is approximately 165179 million, with approximately 62%68% of all households owninghaving a pet.
 
We believe that the following are the main competitive strengths that differentiate 1-800-PetMeds from the competition:
 
 
Channel leader, in an estimated $4.0 billion industry;
 
“1-800-PetMeds” brand name;
 
Licensed pharmacy to conduct business in 50 states, and awarded Vet-VIPPSCM (Veterinary-Verified Internet Pharmacy Practice Site) accreditation by the National Association of Boards of Pharmacy®;
 
Exceptional customer care and support
 
Intellectual Property
 
We conduct our business under the trade name “1-800-PetMeds” and use a family of trade names all containing the term “PetMeds” or “PetMed” in some form.   We believe thisthe “1-800-PetMeds” trade name, which is also our toll-free telephone number, and the “PetMeds” family of trademarks, have added significant value and are an important factor in the marketing of our products. We have also obtained the right to use and control the Internet addresses www.1800petmeds.com, www.1888petmeds.com, www.petmedexpress.com, www.petmed.com, and www.petmeds.com.   We do not expect to lose the ability to use the Internet addresses; however, there can be no assurance in this regard and the loss of these addresses may have a material adverse effect on our financial position and results of operations.  We are the exclusive owners of United States Trademark Registrations for “PetMed Express and Design®,” “1888PetMeds and Design®,” “1-800-PetMeds and Design®,” 1-800-PetMeds®,” and “PetMeds®.”
 
Government Regulation
 
Dispensing prescription medications is governed at the state level by the Boards of Pharmacy, or similar regulatory agencies, of each state where prescription medications are dispensed.  We are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy.  Our current license is valid until February 28, 2013,2015, and prior to that date a renewal application will be submitted to the Board of Pharmacy.  Our pharmacy practice is also licensed and/or regulated by 49 other state pharmacy boards and, with respect to our products, by other regulatory authorities including, but not necessarily limited to, the United States Food and Drug Administration (“FDA”) and the United States Environmental Protection Agency.  As a licensed pharmacy in the State of Florida, we are subject to the Florida Pharmacy Act and regulations promulgated thereunder.  To the extent that we are unable to maintain our license as a community pharmacy with the Florida Board of Pharmacy, or if we do not maintain the licenses granted by other state pharmacy boards, or if we become subject to actions by the FDA, or other enforcement regulators, our distribution of prescription medications to pet owners could cease, which could have a material adverse effect on our financial condition and results of operations.
 
Employees
 
We currently have 207190 full time employees, including: 125110 in customer care and marketing; 3331 in fulfillment and purchasing; 3538 in our pharmacy; 43 in information technology; 3 in administrative positions; and 75 in management.  None of our employees are represented by a labor union, or governed by any collective bargaining agreements.  We consider relations with our employees to be satisfactory.
 
Available Information
 
We file annual, quarterly, and current reports, proxy statements, and other information with the Securities and Exchange Commission (“(SEC).  Our SEC filings, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to the Exchange Act are available free of charge over the Internet on our website at www.1800petmeds.com or at the SEC’s web site at www.sec.gov.  Our SEC filings will be available through our website as soon as reasonably practicable after we have electronically filed or furnished them to the SEC. Information contained on our website is not incorporated by reference into this annual reportAnnual Report on Form 10-K.
 
5

ITEM 1A. RISK FACTORS
 
You should carefully consider the risks and uncertainties described below, and all the other information included in this Annual Report on Form 10-K before you decide to invest in our common stock.  Any of the following risks could materially adversely affect our business, financial condition, or operating results and could result in a loss of your investment.
 
We may inadvertently fail to comply with various state regulations covering the dispensing of prescription pet medications which may subject us to reprimands, sanctions, probations, fines, suspensions, or the loss of one or more of our pharmacy licenses.
 
The sale and delivery of prescription pet medications is generally governed by state laws and state regulations.  Since our pharmacy is located in the State of Florida, the Company is governed by the laws and regulations of the State of Florida.  Each prescription pet medication sale we make is likely also to be covered by the laws of the state where the customer is located.  The laws and regulations relating to the sale and delivery of prescription pet medications vary from state to state, but generally require that prescription pet medications be dispensed with the authorization from a prescribing veterinarian.  To the extent that we are unable to maintain our license as a community pharmacy with the Florida Board of Pharmacy, or if we do not maintain the licenses granted by other state boards, or if we become subject to actions by the FDA, or other enforcement regulators, our distributiondispensing of prescription medications to pet owners could cease, which could have a material adverse effect on our operations.
 
The Company is a party to routine litigation and administrative complaints incidental to its business.  Management does not believe that the resolution of any or all of such routine litigation and administrative complaints is likely to have a material adverse effect on the Company’s financial condition or results of operations.  While we make every effort to fully comply with all applicable state rules, laws, and regulations, from time to time we have been the subject of administrative complaints regarding the authorization of prescriptions prior to shipment.  We cannot assure you that we will not continue to be the subject of administrative complaints in the future.  We cannot guarantee you that we will not be subject to reprimands, sanctions, probations, or fines, or that one or more of our pharmacy licenses will not be suspended or revoked.  If we were unable to maintain our license as a community pharmacy in the State of Florida, or if we are not granted licensure in a state that begins to require licensure, or if one or more of the licenses granted by other state boards should be suspended or revoked, our ability to continue to sell prescription medications and to continue our business as it is presently conducted could be in jeopardy.
 
We currently purchase a portion of our prescription and non-prescription medications from third party distributors and we are not an authorized distributor of these products.  We do not have any guaranteed supply of medications at any pre-established prices.
 
The majority of our sales were attributable to sales of prescription and non-prescription medications.  Historically, substantially all the major pharmaceutical manufacturers have declined to sell prescription and non-prescription pet medications directly to us.  In order to assure a supply of these products, we purchase medications from various secondary sources, including a variety of domestic distributors.  Our business strategy includes seeking to establish direct purchasing arrangements with major pet pharmaceutical manufacturing companies.  If we are not successful in achieving this goal, we will continue to rely upon secondary sources.
 
We cannot guarantee that if we continue to purchase prescription and non-prescription pet medications from secondary sources that we will be able to purchase an adequate supply to meet our customers’ demands, or that we will be able to purchase these products at competitive prices.  As these products represent a significant portion of our sales, our failure to fill customer orders for these products could adversely impact our sales.  If we are forced to pay higher prices for these products to ensure an adequate supply, we cannot guarantee that we will be able to pass along to our customers any increases in the prices we pay for these medications.  This inability to pass along increased prices could materially adversely affect our financial condition and results of operations.
 
6

Our failure to properly manage our inventory may result in excessive inventory carrying costs, or inadequate supply of products, which could materially adversely affect our financial condition and results of operations.
 
Our current product line contains approximately 12003,000 SKUs.  A significant portion of our sales is attributable to products representing approximately 90100 SKUs, including the most popular flea and tick, and heartworm preventative brands.  We need to properly manage our inventory to provide an adequate supply of these products and avoid excessive inventory of the products representing the balance of the SKUs.  We generally place orders for products with our suppliers based upon our internal estimates of the amounts of inventory we will need to fill future orders.  These estimates may be significantly different from the actual orders we receive.
 
In the event that subsequent orders fall short of original estimates, we may be left with excess inventory.  Significant excess inventory could result in price discounts and increased inventory carrying costs.  Similarly, if we fail to have an adequate supply of some SKUs, we may lose sales opportunities.  We cannot guarantee that we will maintain appropriate inventory levels.  Any failure on our part to maintain appropriate inventory levels may have a material adverse effect on our financial condition and results of operations.
 
Resistance from veterinarians to authorize prescriptions, or attempts/efforts on their part to discourage pet owners to purchase from internet mail-order pharmacies could cause our sales to decrease and could materially adversely affect our financial condition and results of operations.
 
Since we began our operations some veterinarians have resisted providing our customers with a copy of their pet’s prescription or authorizing the prescription to our pharmacy staff, thereby effectively preventing us from filling such prescriptions under state law.  We have also been informed by customers and consumers that veterinarians have tried to discourage pet owners from purchasing from internet mail-order pharmacies.  Sales of prescription medications represented approximately 40%44% of our sales for the fiscal year.  Although veterinarians in some states are required by law to provide a pet owner with a prescription if medically appropriate, if the number of veterinarians who refuse to authorize prescriptions should increase, or if veterinarians are successful in discouraging pet owners from purchasing from internet mail-order pharmacies, our sales could decrease and our financial condition and results of operations may be materially adversely affected.
 
Significant portions of our sales are made to residents of eight states.  If we should lose our pharmacy license in one or more of these states, our financial condition and results of operations would be materially adversely affected.
 
While we ship pet medications to customers in all 50 states, approximately 50% of our sales for the fiscal year ended March 31, 20122014 were made to customers located in the states of California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey.   If for any reason our license to operate a pharmacy in one or more of those states should be suspended or revoked, or if it is not granted or renewed, our ability to sell prescription medications to residents of those states would cease and our financial condition and results of operations in future periods would be materially adversely affected.
 
We face significant competition from veterinarians and online and traditional retailers and may not be able to compete profitably with them.
 
We compete directly and indirectly with veterinarians for the sale of pet medications and other health products.  Veterinarians hold a competitive advantage over us because many pet owners may find it more convenient or preferable to purchase these products directly from their veterinarians at the time of an office visit.  We also compete directly and indirectly with both online and traditional retailers.  Both online and traditional retailers may hold a competitive advantage over us because of longer operating histories, established brand names, greater resources, and/or an established customer base.  Online retailers may have a competitive advantage over us because of established affiliate relationships to drive traffic to their website.  Traditional retailers may hold a competitive advantage over us because pet owners may prefer to purchase these products from a store instead of online or through catalog or telephone methods.  In order to effectively compete in the future, we may be required to offer promotions and other incentives, which may result in lower operating margins and adversely affect the results of operations.
 
We also face a significant challenge from our competitors forming alliances with each other, such as those between online and traditional retailers. These relationships may enable both their retail and online stores to negotiate better pricing and better terms from suppliers by aggregating the demand for products and negotiating volume discounts, which could be a competitive disadvantage to us.
7

 
The content of our website could expose us to various kinds of liability, which, if prosecuted successfully, could negatively impact our business.
 
Because we post product and pet health information and other content on our website, we face potential liability for negligence, copyright infringement, patent infringement, trademark infringement, defamation, and/or other claims based on the nature and content of the materials we post.  Various claims have been brought, and sometimes successfully prosecuted, against Internet content distributors.  We could be exposed to liability with respect to the unauthorized duplication of content or unauthorized use of other parties’ proprietary technology.  Although we maintain general liability insurance, our insurance may not cover potential claims of this type, or may not be adequate to indemnify us for all liability that may be imposed.  Any imposition of liability that is not covered by insurance, or is in excess of insurance coverage, could materially adversely affect our financial condition and results of operations.
 
We may not be able to protect our intellectual property rights, and/or we may be found to infringe on the proprietary rights of others.
 
We rely on a combination of trademarks, trade secrets, copyright laws, and contractual restrictions to protect our intellectual property rights.  These afford only limited protection. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy our non-prescription private label generic equivalents, when and if developed, as well as aspects of our sales formats, or to obtain and use information that we regard as proprietary, including the technology used to operate our website and our content, and our trademarks.  Litigation or proceedings before the United States Patent and Trademark Office or other bodies may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets and domain names, or to determine the validity and scope of the proprietary rights of others.  Any litigation or adverse proceeding could result in substantial costs and diversion of resources, and could seriously harm our business and operating results.  Third parties may also claim infringement by us with respect to past, current, or future technologies.  We expect that participants in our market will be increasingly involved in infringement claims as the number of services and competitors in our industry segment grows.  Any claim, whether meritorious or not, could be time-consuming, result in costly litigation, cause service upgrade delays, or require us to enter into royalty or licensing agreements.  These royalty or licensing agreements might not be available on terms acceptable to us or at all.
 
If we are unable to protect our Internet addresses or to prevent others from using Internet addresses that are confusingly similar, our business may be adversely impacted.
 
Our Internet addresses, www.1800petmeds.com, www.1888petmeds.com, www.petmedexpress.com, www.petmed.com, and www.petmeds.com are critical to our brand recognition and our overall success.  If we are unable to protect these Internet addresses, our competitors could capitalize on our brand recognition.  There may be similar Internet addresses used by competitors.  Governmental agencies and their designees generally regulate the acquisition and maintenance of Internet addresses.  The regulation of Internet addresses in the United States and in foreign countries has changed, and may undergo further change in the near future.  Furthermore, the relationship between regulations governing Internet addresses and laws protecting trademarks and similar proprietary rights is unclear.  Therefore, we may not be able to protect our own Internet addresses, or prevent third parties from acquiring Internet addresses that are confusingly similar to, infringe upon, or otherwise decrease the value of our Internet addresses.
 
Since all of our operations are housed in a single location, we are more susceptible to business interruption in the event of damage to or disruptions in our facility.
 
Our headquarters and distribution center are located in two buildings in one location in South Florida, and most of our shipments of products to our customers are made from this sole distribution center.  We have no present plans to establish any additional distribution centers or offices.  Because we consolidate our operations in one location, we are more susceptible to power and equipment failures, and business interruptions in the event of fires, floods, and other natural disasters than if we had additional locations.  Furthermore, because we are located in South Florida, which is a hurricane-sensitive area, we are particularly susceptible to the risk of damage to, or total destruction of, our headquarters and distribution center and surrounding transportation infrastructure caused by a hurricane.  We cannot assure you that we are adequately insured to cover the amount of any losses relating to any of these potential events, business interruptions resulting from damage to or destruction of our headquarters and distribution center, or power and equipment failures relating to our call center or websites, or interruptions or disruptions to major transportation infrastructure, or other events that do not occur on our premises.  The occurrence of one or more of these events could adversely impact our ability to generate revenues in future periods.
 
8

Our operating results are difficult to predict and may fluctuate, and a portion of our sales are seasonal.
 
Factors that may cause our operating results to fluctuate include:
 
 
Our ability to obtain new customers at a reasonable cost, retain existing customers, or encourage reorders;
 
Our ability to increase the number of visitors to our website, or our ability to convert visitors to our website into customers;
 
The mix of medications and other pet products sold by us;
 
Our ability to manage inventory levels or obtain an adequate supply of products;
 
Our ability to adequately maintain, upgrade, and develop our website, the systems that we use to process customers’ orders and payments, or our computer network;
 
Increased competition within our market niche;
 
Price competition;
 
New products introduced to the market, including generics;
 
Increases in the cost of advertising;
 
The amount and timing of operating costs and capital expenditures relating to expansion of our product line or operations;
 
Disruption of our toll-free telephone service, technical difficulties, or systems and Internet outages or slowdowns; and
 
Unfavorable general economic trends.
 
Because our operating results are difficult to predict, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.  The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications.  For the quarters ended June 30, 2011,2013, September 30, 2011,2013, December 31, 2011,2013, and March 31, 2012,2014, Company sales were 31%32%, 24%26%, 21%, and 24%21%, respectively.  In addition to the seasonality of our sales, our annual and quarterly operating results have fluctuated in the past and may fluctuate significantly in the future due to a variety of factors, including weather, many of which are out of our control.  Any change in one or more of these factors could materially adversely affect our financial condition and results of operations in future periods.
 
Our stock price fluctuates from time to time and may fall below expectations of securities analysts and investors, and could subject us to litigation, which may result in you suffering a loss on your investment.
 
The market price of our common stock may fluctuate significantly in response to a number of factors, many of which are out of our control.  These factors include: quarterly variations in operating results; changes in accounting treatments or principles; announcements by us or our competitors of new products and services offerings; significant contracts, acquisitions, or strategic relationships; additions or departures of key personnel; any future sales of our common stock or other securities; stock market price and volume fluctuations of publicly-traded companies; and general political, economic, and market conditions.
 
In some future quarter our operating results may fall below the expectations of securities analysts and investors, which could result in a decrease in the trading price of our common stock.  In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of its securities.  We may be the target of similar litigation in the future.  Securities litigation could result in substantial costs and divert management’s attention and resources, which could seriously harm our business and operating results.
 
We may issue additional shares of preferred stock that could defer a change of control or dilute the interests of our common stockholders.  Our charter documents could defer a takeover effort which could inhibit your ability to receive an acquisition premium for your shares.
 
Our charter permits our Board of Directors to issue up to 5.0 million shares of preferred stock without stockholder approval.  Currently there are 2,500 shares of our Convertible Preferred Stock issued and outstanding.  This leaves a little less than 5.0 million shares of preferred stock available for issuance at the discretion of our Board of Directors.  These shares, if issued, could contain dividend, liquidation, conversion, voting, or other rights which could adversely affect the rights of our common stockholders and which could also be utilized, under some circumstances, as a method of discouraging, delaying, or preventing a change in control.  Provisions of our articles of incorporation, bylaws and Florida law could make it more difficult for a third party to acquire us, even if many of our stockholders believe it is in their best interest.
 
9

The United States Environmental Protection Agency (“EPA”) has announced its intention to increase restrictions on flea and tick products and to caution consumers to use these products with extra care.  The Company’s sales and profits in future periods could be adversely impacted if sales for these products decline.
 
The EPA is takinghas taken a series of actions to increase the safety of spot-on pesticide products for flea and tick control for cats and dogs.  In 2008 the EPA received 44,000 complaints about certain “spot-on” pest prevention products, including some flea and tick control products that the Company currently sells.  The complaints reported adverse reactions ranging from mild effects such as skin irritations to more serious effects such as seizures and, in some cases, death of the pet.  Since that time, the EPA received additional information from the pet spot-on pesticide registrants and others and began an intensive evaluation of these products. Among immediate actions that the EPA is going to pursue are: requiring manufacturers of spot-on pesticide products to improve labeling, making instructions clearer to prevent product misuse; requiring more precise label instructions to ensure proper dosage per pet weight; requiring clear markings to differentiate between dog and cat products, and disallowing similar brand names for dog and cat products. There can be no assurances that this action or future actions by the EPA will not adversely affect our future sales and profits.profits.
 
A failure of our information systems or any security breach or unauthorized disclosure of confidential information could have a material adverse effect on our business.
 
Our business is dependent upon the efficient operation of our information systems. In particular, we rely on our information systems to effectively manage our business model strategy, with tools to track and manage sales, inventory, marketing, customer service efforts, the preparation of our consolidated financial and operating data, credit card information, and customer information.  The failure of our information systems to perform as designed or the failure to maintain and enhance or protect the integrity of these systems could disrupt our business operations, impact sales and the results of operations, expose us to customer or third-party claims, or result in adverse publicity.  Additionally, we collect, process, and retain sensitive and confidential customer information in the normal course of our business.  Despite the security measures we have in place and any additional measures we may implement in the future, our facilities and systems, and those of our third-party service providers, could be vulnerable to security breaches, computer viruses, lost or misplaced data, programming errors, human errors, acts of vandalism, or other events.  Any security breach or event resulting in the misappropriation, loss, or other unauthorized disclosure of confidential information, whether by us directly or our third-party service providers, could damage our reputation, expose us to the risks of litigation and liability, disrupt our business, or otherwise affect our results of operations.
 
10

ITEM 1B.  UNRESOLVED STAFF COMMENTS
 
None
 
ITEM 2.  PROPERTIES
 
Our facilities, including our principal executive offices, are located at 1441 S.W. 29th Avenue and 2900 Gateway Drive, Pompano Beach, Florida 33069.  The Company leases its 65,300 square foot executive offices, warehouse facility and customer service and pharmacy contact centers under a non-cancelable operating lease, through May 31, 2015.  On April 30, 2014, the Company entered into a seventh amendment of its operating lease to extend its existing lease until December 1, 2016.  The Company is responsible for certain maintenance costs, taxes, and insurance under this lease.  The future minimum annual lease payments are as follows: $767,000 for fiscal 2013, $784,000 for fiscal 2014, $794,000 for fiscal 2015, and $133,000$796,000 for fiscal 2016, and $585,000 for fiscal 2017, for a lease payment total of $2.5$2.2 million.  Rent expense was $745,000, $724,000,$785,000, $767,000, and $703,000$745,000 for the fiscal years ended March 31, 2012, 20112014, 2013 and 2010,2012, respectively.  We believe that our facilities are sufficient for our current needs and are in good condition in all material respects.
 
ITEM 3.  LEGAL PROCEEDINGS
In October 2009, the Company was notified that it was named as a defendant in a multi-defendant lawsuit, filed in the United States District Court for the Eastern District of Texas, Marshall Division, seeking declaratory, injunctive, and monetary relief styled Charles E. Hill & Associates, Inc. v. ABT Electronics, Inc., et al, Cause No. 2:09-CV-313.  The lawsuit alleges that the Company is infringing on patents related to electronic catalog systems.  From the outset, the vendor that provides the Company with the Internet software had been defending and indemnifying the Company.  However, effective February 15, 2011, the company that acquired this vendor declined to provide any further indemnification of the Company.  On October 5, 2011, the parties engaged in court-ordered mediation, which was unsuccessful.  Without admitting any liability or wrongdoing, and with no finding or admission as to the merit or lack of merit of any claim or defense asserted in connection with the litigation, in May 2012, the Company entered into a licensing agreement, for a confidential amount, and a Stipulation of Dismissal was filed with the Court, dismissing the lawsuit against the Company.
 
The Company has settled complaints that had been filed with various states’ pharmacy boards in the past.  There can be no assurances made that other states will not attempt to take similar actions against the Company in the future.  The Company initiates litigation to protect its trade or service marks.  There can be no assurance that the Company will be successful in protecting its trade or service marks.  Legal costs related to the above matters are expensed as incurred.
 
ITEM 4. MINE SAFETY DISCLOSURES
 
Not applicable.
11

 
PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

      Our common stock is traded on the NASDAQ Global Select Market (“NASDAQ”) under the symbol “PETS.”  The prices set forth below reflect the range of high and low closing sale prices per share in each of the quarters of fiscal 20122014 and 20112013 as reported by the NASDAQ.
 
 Fiscal 2012: High  Low 
 First Quarter $15.89  $11.53 
 Second Quarter $12.28  $8.91 
 Third Quarter $10.55  $8.57 
 Fourth Quarter $12.72  $10.17 
          
 Fiscal 2011: High  Low 
 First Quarter $24.50  $17.34 
 Second Quarter $18.45  $15.45 
 Third Quarter $18.80  $15.21 
 Fourth Quarter $17.89  $14.39 
Fiscal 2014: High  Low 
First Quarter $13.73  $12.37 
Second Quarter $17.17  $12.82 
Third Quarter $16.94  $14.58 
Fourth Quarter $16.65  $12.62 
       
Fiscal 2013: High  Low 
First Quarter $13.76  $11.07 
Second Quarter $12.35  $9.36 
Third Quarter $12.39  $9.95 
Fourth Quarter $14.37  $11.09 
 
There were 8883 holders of record of our common stock at May 28, 2012,27, 2014, and approximately 12,00018,000 of our holders are “street name” or beneficial holders, whose shares are held by banks, brokers, or other financial institutions.

Dividend PolicyDuring fiscal 2013 and 2014, our Board of Directors declared the following dividends:

  Per Share   Total Amount  
Declaration Date Dividend Record Date (In thousands) Payment Date
           
May 7, 2012 $0.150 May 14, 2012 $3,050 May 25, 2012
July 30, 2012 $0.150 August 13, 2012 $3,049 August 24, 2012
October 29, 2012 $0.150 November 9, 2012 $3,001 November 23, 2012
December 3, 2012 $1.000 December 14, 2012 $20,001 December 24, 2012
January 28, 2013 $0.150 February 8, 2013 $3,000 February 22, 2013
           
May 3, 2013 $0.150 May 15, 2013 $3,016 May 24, 2013
July 26, 2013 $0.170 August 12, 2013 $3,433 August 23, 2013
October 28, 2013 $0.170 November 8, 2013 $3,432 November 22, 2013
January 30, 2014 $0.170 February 12, 2014 $3,432 February 21, 2014

On August 3, 2009,May 5, 2014, the Company’s Board of Directors declared its firsta quarterly dividend of $0.10$0.17 per share on its common stock.  On August 2, 2010,The $3.4 million dividend was paid on May 23, 2014, to shareholders of record at the Company’s Boardclose of Directors increased the quarterly dividend to $0.125 per share, and thenbusiness on January 27, 2012, the Company’s Board of Directors increased the quarterly dividend to $0.15 per share.May 16, 2014.  The Company intends to continue to pay regular quarterly dividends; however the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.
During fiscal 2012, our Board of Directors declared the following dividends:
   Per Share   Total Amount  
 Declaration Date Dividend Record Date (In thousands) Payment Date
 
 
May 6, 2011
 $0.125 May 16, 2011 $2,782 May 27, 2011
 July 29, 2011 $0.125 August 12, 2011 $2,626 August 26, 2011
 October 28, 2011 $0.125 November 11, 2011 $2,542 November 25, 2011
 January 27, 2012 $0.150 February 10, 2012 $3,051 February 24, 2012
On May 4, 2012, the Company’s Board of Directors declared a quarterly dividend of $0.15 per share on its common stock.  The $3.1 million dividend was paid on May 25, 2012, to shareholders of record at the close of business on May 14, 2012.

Share Repurchase Plan

On November 8, 2006, the Company’sCompanys Board of Directors approved a share repurchase plan of up to $20.0 million.  On October 31, 2008, November 1, 2010, and August 1, 2011, the Company’s Board of Directors approved a second, third, and fourth share repurchase plan, respectively, each for an additional $20.0 million.  The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company’s discretion, subject to market conditions and other factors, in accordance with Securities and Exchange Commission requirements.  There can be no assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company may discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements.  Shares purchased pursuant to the share repurchase plan will either be cancelled or held in the Company’sCompanys treasury.
12

 
During fiscal 20122014 the Company repurchased approximately 2.1 milliondid not repurchase any shares, of the Company’s outstanding common stock for approximately $23.7 million, averaging approximately $11.36 per share.  Asand as of March 31, 2012,2014, the Company had approximately $14.0$10.2 million remaining under the Company’s share repurchase plan.  During fiscal 20112013 the Company repurchased approximately 791,000397,000 shares of the Company’s outstanding common stock for approximately $12.2$3.9 million, averaging approximately $15.47$9.74 per share.  All shares repurchased in fiscal 2012 and 20112013 were subsequently retired.  Since the inception of the share repurchase plan, approximately 5.25.6 million shares have been repurchased under the plan for approximately $66.0$69.8 million, averaging approximately $12.75$12.54 per share, with approximately $14.0 million remaining available for repurchase, as of May 28, 2012.share.

Performance Graph

Set forth below is a line graph comparing the five year cumulative performance of our Common Stock with the Standard & Poor’s Composite-500 Stock Index (the “S&P 500”), the Nasdaq Composite, and the Russell 2000, from March 31, 20072009 to March 31, 2012.2014.  The graph assumes that $100 was invested on March 31, 20072009 in each of our Common Stock, the S&P 500, the Nasdaq Composite, and the Russell 2000 and2000.  Because we have historically paid dividends on a quarterly basis, the graph assumes that all dividends were reinvested.  The performance graph and related information below shall not be deemed “filed” with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.
 
Performance graph data:

  Fiscal Year Ended March 31,  Fiscal Year Ended March 31,
 2007  2008  2009  2010  2011  2012   2009   2010   2011   2012   2013   2014 
Nasdaq Composite  100.00   94.11   63.12   99.02   114.84   127.66   100.00   158.29   185.49   210.25   218.09   285.76 
S&P 500  100.00   93.09   56.15   82.30   93.31   99.13   100.00   149.77   173.20   187.99   214.24   261.06 
Russell 2000  100.00   85.92   52.80   84.75   105.35   103.70   100.00   162.77   204.75   204.37   237.69   296.87 
PetMed Express, Inc.  100.00   93.59   139.07   187.09   133.84   104.47   100.00   136.80   100.65   82.40   102.52   107.36 
13


Securities Authorized for Issuance under Equity Compensation Plans

The following table sets forth securities authorized for issuance under equity compensation plans, including individual compensation arrangements, by us under our 2006 Employee Equity Compensation Restricted Stock Plan and 2006 Outside Director Equity Compensation Restricted Stock Plan as of March 31, 2012:2014:

EQUITY COMPENSATION PLAN INFORMATION 
(In thousands, except for per share amounts) 
  Number of securities     Number of securities 
  to be issued upon  Weighted average  remaining available 
  exercise of outstanding  exercise price of  for future issuance 
  options, warrants  outstanding options,  under equity 
Plan category and rights  warrants and rights  compensation plans 
          
2006 Employee Restricted Stock Plan  542   -   458 
             
2006 Director Restricted Stock Plan  152   -   48 
             
Total  694       506 
EQUITY COMPENSATION PLAN INFORMATION
(In thousands, except for per share amounts)
 
14

  Number of securities     Number of securities 
  to be issued upon  Weighted average  remaining available 
  exercise of outstanding  exercise price of  for future issuance 
  options, warrants  outstanding options,  under equity 
Plan category and rights  warrants and rights  compensation plans 
          
2006 Employee Restricted Stock Plan  732   -   478 
             
2006 Director Restricted Stock Plan  212   -   272 
             
Total  944       750 
 
ITEM 6.  SELECTED FINANCIAL DATA

The following selected financial data should be read together with “Management’sManagement’s Discussion and Analysis of Financial Condition and Results of Operations, the Consolidated Financial Statements and notes thereto, and other financial information included elsewhere in this Annual Report on Form 10-K.  The Consolidated Statements of Income data set forth below for the fiscal years ended March 31, 2012, 2011,2014, 2013, and 20102012 and the Consolidated Balance Sheet data as of March 31, 20122014 and 20112013 have been derived from our audited Consolidated Financial Statements which are included elsewhere in this Annual Report on Form 10-K.  The Consolidated Statements of Income data set forth below for the fiscal years ended March 31, 20092011 and 20082010 and the Consolidated Balance Sheet data as of March 31, 2010, 20092012, 2011 and 20082010 have been derived from our audited Consolidated Financial Statements which are not included in this Annual Report on Form 10-K.
 
CONSOLIDATED STATEMENTS OF INCOME DATA
(In thousands, except for per share amounts)
               
   Fiscal Year Ended March 31,   Fiscal Year Ended March 31, 
 2012  2011  2010  2009  2008  2014  2013  2012  2011  2010 
                              
Sales $238,250  $231,642  $238,266  $219,412  $188,336  $233,391  $227,829  $238,250  $231,642  $238,266 
Cost of sales  158,085   147,686   146,405   134,085   114,122   155,774   150,708   158,085   147,686   146,405 
Gross profit  80,165   83,956   91,861   85,328   74,214   77,617   77,121   80,165   83,956   91,861 
Operating expenses  54,143   50,932   51,319   51,127   46,218   49,399   50,116   54,143   50,932   51,319 
Net income  16,659   20,871   26,002   22,976   20,022   17,972   17,165   16,659   20,871   26,002 
Net income per common share:                                        
Basic  0.81   0.93   1.15   0.99   0.83   0.90   0.86   0.81   0.93   1.15 
Diluted  0.80   0.92   1.14   0.98   0.82   0.90   0.86   0.80   0.92   1.14 
Weighted average number of common shares outstanding:
                    
Weighted average number of                    
common shares outstanding:                    
Basic  20,613   22,514   22,617   23,306   24,088   19,901   19,926   20,613   22,514   22,617 
Diluted  20,708   22,643   22,746   23,482   24,299   20,043   20,049   20,708   22,643   22,746 
Cash dividends declared per common share
  0.525   0.475   0.300   -   - 
Cash dividends declared per                    
common share  0.660   1.600   0.525   0.475   0.300 
                    
CONSOLIDATED BALANCE SHEET DATA
(In thousands)
CONSOLIDATED BALANCE SHEET DATA
(In thousands)
              
  March 31, 
  2014   2013   2012   2011   2010 
                    
Working capital $66,116  $59,760  $78,216  $80,643  $79,412 
Total assets  78,375   73,179   91,064   106,287   104,170 
Total liabilities  8,158   9,165   9,883   9,282   7,313 
Shareholders equity
  70,217   64,014   81,181   97,005   96,857 
                    
NON FINANCIAL DATA (UNAUDITED)NON FINANCIAL DATA (UNAUDITED)
(In thousands)(In thousands)
 March 31, 
  2014   2013   2012   2011   2010 
                    
New customers acquired  597   630   722   645   815 
Total accumulated customers (1)  8,057   7,460   6,830   6,108   5,463 
                    
(1) includes both active and inactive customers(1) includes both active and inactive customers        
 
CONSOLIDATED BALANCE SHEET DATA DATA
(In thousands)
    March 31, 
  2012  2011  2010  2009  2008 
                
Working capital $78,216  $80,643  $79,412  $54,630  $38,804 
Total assets  91,064   106,287   104,170   81,963   73,455 
Total liabilities  9,883   9,282   7,313   6,995   6,421 
Shareholders’ equity  81,181   97,005   96,857   74,968   67,034 
NON FINANCIAL DATA (UNAUDITED)
(In thousands)
    March 31, 
  2012  2011  2010  2009  2008 
                
New customers acquired  722   645   815   802  710 
Total accumulated customers (1)  6,830   6,108   5,463   4,648   3,846 
(1) includes both active and inactive customers
15

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Summary

PetMed Express was incorporated in the state of Florida in January 1996.  The Company’s common stock is traded on the NASDAQ Global Select Market under the symbol “PETS.”  The Company began selling pet medications and other pet health products in September 1996.  In March 2010 the Company started offering for sale additional pet supplies on its website, and these items are drop shipped to customers by third party vendors. Presently, the Company’s product line includes approximately 1,2003,000 of the most popular pet medications, health products, and supplies for dogs and cats.

 
The Company markets its products through national television, online, and direct mail/print advertising campaigns which aim to increase the recognition of the “1-800-PetMeds” brand name, and “PetMeds” family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases.  Approximately 75%79% of all sales were generated via the Internet in fiscal 2012,2014, compared to 71%77% in fiscal 2011.2013.  The Company’s sales consist of products sold mainly to retail consumers.  The Company’s sales returns average was approximately 1.5% of sales for the fiscal year ended March 31, 2012 and approximately 1.4% for the fiscal year ended March 31, 2011.  The twelve-month average purchase was approximately $76$75 and $79$73 per order for the fiscal years ended March 31, 20122014 and 2011,2013, respectively.

Critical Accounting Policies

Our discussion and analysis of our financial condition and the results of our operations are based upon our Consolidated Financial Statements and the data used to prepare them.  The Company’s Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America.  On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, long term investments, and income taxes.  We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information.  Actual results may differ from these estimates under different assumptions or conditions.  Our estimates are guided by observing the following critical accounting policies.

Revenue recognition

The Company generates revenue by selling pet medication products and pet supplies primarily to retail consumers.  The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the customer.  Outbound shipping and handling fees are included in sales and are billed upon shipment.  Shipping expenses are included in cost of sales.  The majority of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days.  Credit card sales minimize accounts receivable balances relative to sales.  The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card charge-backs or insufficient funds checks.  The Company determines its estimates of the uncollectibility of accounts receivable by analyzing historical bad debts and current economic trends.  At March 31, 2012 and 2011 theThe allowance for doubtful accounts was approximately $7,000 at March 31, 2014, compared to $5,000 and $6,000, respectively.at March 31, 2013.

Valuation of inventory

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or market value using a weighted average cost method.  The Company writes down its inventory for estimated obsolescence.  The inventory reserve was approximately $66,000$90,000 and $63,000$79,000 as of March 31, 20122014 and 2011,2013, respectively.

Advertising

The Company’s advertising expense consists primarily of television advertising, Internet marketing, and direct mail/print advertising.  Television advertising costs are expensed as the advertisements are televised.  Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded.
16

Accounting for income taxes

The Company accounts for income taxes under the provisions of ASC Topic 740, (“Accounting for Income Taxes”), which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the Consolidated Financial Statements or tax returns.  Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities, and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

Results of Operations

The following should be read in conjunction with the Company’s Consolidated Financial Statements and the related notes thereto included elsewhere herein.  The following table sets forth, as a percentage of sales, certain operating data appearing in the Company’s Consolidated Statements of Comprehensive Income:
 
 Fiscal Year Ended March 31, 
 Fiscal Year Ended March 31,          
 
 
2012
  2011  2010  2014  2013  2012 
                  
Sales  100.0%  100.0%  100.0%  100.0%  100.0%  100.0%
Cost of sales  66.3   63.8   61.4   66.7   66.1   66.3 
                        
Gross profit  33.7   36.2   38.6   33.3   33.9   33.7 
                        
Operating expenses:                        
General and administrative  9.4   9.6   9.4   9.2   9.5   9.4 
Advertising  12.8   11.8   11.6   11.6   12.0   12.8 
Depreciation  0.6   0.6   0.6   0.4   0.5   0.6 
Total operating expenses  22.8   22.0   21.6   21.2   22.0   22.8 
                        
Income from operations  10.9   14.2   17.0   12.1   11.9   10.9 
                        
Total other income  0.2   0.2   0.1   0.1   0.1   0.2 
                        
Income before provision for income taxes  11.1   14.4   17.1   12.2   12.0   11.1 
                        
Provision for income taxes  4.1   5.4   6.2   4.5   4.5   4.1 
                        
Net income  7.0%  9.0%  10.9%  7.7%  7.5%  7.0%

Fiscal 20122014 Compared to Fiscal 20112013

Sales

Sales increased by approximately $6.7$5.6 million, or 2.9%2.4%, to approximately $238.3$233.4 million for the fiscal year ended March 31, 2012,2014, from approximately $231.6$227.8 million for the fiscal year ended March 31, 2011.2013.  The increase in sales for the fiscal year ended March 31, 2012 was primarily due to increased new order and reorder sales.  The increase in new order sales may2014 can be attributed to increased advertising expenses, with flat customer acquisition costs.reorder sales, offset by a reduction to new order sales.  Our sales increase was also due to an increase in the average order size during the year.  The Company acquired approximately 722,000597,000 new customers for the year ended March 31, 2012,2014, compared to approximately 645,000630,000 new customers for the same period the prior year.
17

 
The following chart illustrates sales by various sales classifications:
 
Sales (In thousands) 2014  %  2013  %  $ Variance  % Variance 
  Year Ended March 31,                         
Sales (In thousands) 2012  %  2011  %  $ Variance  % Variance 
Reorder Sales
 $186,991   78.5% $184,341   79.6% $2,650   1.4% $191,205   81.9% $184,814   81.1% $6,391   3.5%
New Order Sales $51,259   21.5% $47,301   20.4% $3,958   8.4% $42,186   18.1% $43,015   18.9% $(829)  -1.9%
Total Net Sales $238,250   100.0% $231,642   100.0% $6,608   2.9% $233,391   100.0% $227,829   100.0% $5,562   2.4%
Internet Sales $178,758   75.0% $165,473   71.4% $13,285   8.0% $184,356   79.0% $175,984   77.2% $8,372   4.8%
Contact Center Sales $59,492   25.0% $66,169   28.6% $(6,677)  -10.1% $49,035   21.0% $51,845   22.8% $(2,810)  -5.4%
Total Net Sales $238,250   100.0% $231,642   100.0% $6,608   2.9% $233,391   100.0% $227,829   100.0% $5,562   2.4%
 
SalesFuture sales may be adversely affected in fiscal 2013 due to increased competition and consumers giving more consideration to price and trading down to less expensive brands, including generics.  In response to these trends, the Company will maintain a more aggressive advertising and pricing strategy combined with expanding our product offerings to pet supplies and generics.  This more aggressive pricing strategy has resulted in a decrease to gross profit margins, and noprice.  No guarantees can be made that the Company’s efforts will be successful, or that sales will grow in the future.  The majority of our product sales arewere affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications.  For the quarters ended June 30, September 30, December 31, and March 31 of fiscal 2012,2014, the Company’s sales were approximately 31%32%, 24%26%, 21%, and 24%21%, respectively.
In January 2012,  For the manufacturer Novartis Consumer Health, Inc. announced that it halted productionquarters ended June 30, September 30, December 31, and March 31 of their animal health products, includingfiscal 2013, the following brands: Sentinel®Company’s sales were approximately 30%, Interceptor®26%, Program®, Deramaxx®22%, and Clomicalm®.  This disruption is industry wide, and at this time, there is no expected date for production to resume.  We are currently asking prescribing veterinarians to prescribe alternate brands as we run out22%, respectively.  Sales in the March quarter of inventory.   This disruption in production hasfiscal 2014 were negatively impacted our sales, and ifby the disruption is prolonged it may negatively impact future sales.colder-than-normal weather.

Cost of sales

Cost of sales increased by $10.4$5.1 million, or 7.0%3.4%, to $158.1$155.8 million for the fiscal year ended March 31, 2012,2014, from $147.7$150.7 million for the fiscal year ended March 31, 2011.2013.  The increase in cost of sales is directly related to increased sales and increased product costs.sales.  As a percentage of sales, cost of sales was 66.3%66.7% in fiscal 2012,2014, as compared to 63.8%66.1% in fiscal 2011.2013.  The cost of sales percentage increase can be mainly attributed to more aggressive sales pricingan increase in product costs and increasesan increase in our product costs.promotional discounts.

Gross profit

Gross profit decreasedincreased by $3.8 million, or 4.5%,$496,000, to $80.2$77.6 million for the fiscal year ended March 31, 2012,2014, from $84.0$77.1 million for the fiscal year ended March 31, 2011.2013.  Gross profit as a percentage of sales for fiscal 2012 and 20112014 was 33.7% and 36.2%33.3% compared to 33.9%, respectively.for fiscal 2013.  The gross profit percentage decrease can be mainly attributed to more aggressive sales promotionsan increase in product costs and increasesan increase in our product costs.promotional discounts.

General and administrative expenses

General and administrative expenses increaseddecreased by $163,000,$240,000, or 0.7%1.1%, to $22.4$21.4 million for the fiscal year ended March 31, 20122014 from $22.2$21.6 million for the fiscal year ended March 31, 2011.2013.  The increasedecrease in general and administrative expenses for the fiscal year ended March 31, 20122014 was primarily due to the following: a $307,000 increase$331,000 reduction in payroll expenses relating to the customer care and pharmacy departments and a $220,000 increase in property expenses which wasexpense primarily related to our website.a reduction in stock based compensation; a $67,000 decrease in office expenses; a $37,000 decrease in licenses and fees; and a $36,000 decrease in telephone expenses.  Offsetting the increasedecrease was a $220,000 decrease in professional fees, with the majority of the decrease relating to investor relations and pharmacy fees, a $98,000 decrease$155,000 increase in bank service fees due to increased sales; a reduction$40,000 increase in credit card fees,bad debt expense; and a $46,000$36,000 net decreaseincrease in other expenses including telephone, office expenses,professional fees and licenses.travel expense.  General and administrative expenses as a percentage of sales was 9.4%9.2% compared to 9.6%9.5% for the fiscal years ended March 31, 20122014 and 2011,2013, respectively.  The decrease in general and administrative expenses as a percentage of sales can mainly be attributed to a reductionan increase in bank service fees and professional feessales in fiscal 2012.2014.
18


Advertising expenses

Advertising expenses increaseddecreased by approximately $3.0 million, or 11.0%,$253,000 to approximately $30.4$27.2 million for the year ended March 31, 2012,2014, from approximately $27.4 million for the year ended March 31, 2011.2013.  The increasedecrease in advertising expenses for fiscal 20122014 can be mainly attributed to a more aggressive advertising strategy during the year.reduction in print advertising.  The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $42$46 for both the fiscal yearsyear ended March 31, 2012 and 2011.  2014, compared to $44 for the fiscal year ended March 31, 2013.
Advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, increased advertising spending, and price competition.  Historically, the advertising environment fluctuates due to supply and demand.  A more favorable advertising environment may positively impact future new order sales, whereas a less favorable advertising environment may negatively impact future new order sales.
As a percentage of sales, advertising expense was 12.811.6 % and 11.8%12.0% for the fiscal years ended March 31, 20122014 and 2011,2013, respectively.  The increasedecrease in advertising expense as a percentage of total sales for the fiscal year ended March 31, 20122014 can be attributed to increased sales and a more aggressivereduction in advertising strategy during fiscal 2012.expense.  The Company currently anticipates advertising as a percentage of sales to be approximately 13%12% for fiscal 2013.2015.  However, the advertising percentage will fluctuate quarter to quarter due to seasonality and advertising availability.  For the fiscal year ended March 31, 2012,2014, quarterly advertising expenses as a percentage of sales ranged between 11%9% and 14%.

Depreciation

Depreciation increaseddecreased by approximately $36,000,$224,000, to approximately $1.4$867,000 for the year ended March 31, 2014, from approximately $1.1 million for the year ended March 31, 2012, from approximately $1.4 million for the year ended March 31, 2011.2013.  This increasedecrease to depreciation for the year ended March 31, 20122014 can be attributed to a reduction in new property and equipment additions, relating to the warehouse, pharmacy, and customer call center over the past 2 fiscal years.an increase in fully depreciated fixed assets.

Other income

Other income increaseddecreased by approximately $96,000,$120,000, to approximately $349,000$181,000 for the year ended March 31, 20122014 from approximately $253,000$301,000 for the year ended March 31, 2011.2013.  The increasedecrease to other income for the year ended March 31, 20122014 can be attributed to the recognition of a federal tax penalty in fiscal 2011.decreased interest income.  Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $14.0$10.2 million remaining as of March 31, 2012,2014, on any quarterly dividend payment, or on its operating activities.

Provision for income taxes

For the fiscal years ended March 31, 20122014 and 2011,2013, the Company recorded an income tax provision for approximately $9.7$10.4 million and $12.4$10.1 million, respectively.  The effective tax rate for the fiscal years ended March 31, 20122014 and 20112013 were 36.8%36.7% and 37.3%37.1%, respectively.  The effective tax rate decrease for the fiscal year ended March 31, 2012,2014, was due to a one-time $280,000benefit related to a fiscal 2013 income tax adjustment,over-accrual, which was recognized in fiscal 2011,2014, compared to reconcile the remaining net operating loss carryforward.a one-time charge related to a fiscal 2012 income tax under-accrual, which was recognized in fiscal 2013.  The Company estimates its effective tax rate will be approximately 37.0% for fiscal 2013.2015.

Net income

Net income decreasedincreased by approximately $4.2 million,$807,000, or 20.2%4.7%, to approximately $16.7$18.0 million for the fiscal year ended March 31, 20122014 from approximately $20.9$17.2 million for the fiscal year ended March 31, 2011.2013.  The decreaseincrease was primarily due to an increase in sales and a decrease in gross profit margins as a result of more aggressive pricing, and an increase in advertising spending to revitalize salesoperating expenses in fiscal 2012.2014.

Fiscal 20112013 Compared to Fiscal 20102012

Sales

Sales decreased by approximately $6.7$10.5 million, or 2.8%4.4%, to approximately $231.6$227.8 million for the fiscal year ended March 31, 2011,2013, from approximately $238.3 million for the fiscal year ended March 31, 2010.2012.  The decreasereduction in sales for the fiscal year ended March 31, 2011 was primarily due2013 can be attributed to decreased new order sales offset by an increase in reorder sales.  The decreasea reduction in new order sales, may be attributeddue to an increasereduced advertising spending, and reorder sales.  Our sales were negatively impacted because of the unavailability of Novartis brands during the year due to the manufacturer’s suspended production.  Our sales were also down because of a decline in customer
19

acquisition costs,average order size, which was due to a reductionchange in response rates, as a result ofproduct mix to lower priced items, including generics, additional discounts given, and increased competition and softer demand.competition.  The Company acquired approximately 645,000630,000 new customers for the year ended March 31, 2011,2013, compared to approximately 815,000722,000 new customers for the same period the prior year.
 
The following chart illustrates sales by various sales classifications:

Year Ended March 31,Year Ended March 31, Year Ended March 31,
Sales (In thousands) 2011  %  2010  %  $ Variance  % Variance  2013  %  2012  %  $ Variance  % Variance 
                                          
Reorder Sales $184,341   79.6% $177,805   74.6% $6,536   3.7% $184,814   81.1% $186,991   78.5% $(2,177)  -1.2%
New Order Sales $47,301   20.4% $60,461   25.4% $(13,160)  -21.8% $43,015   18.9% $51,259   21.5% $(8,244)  -16.1%
Total Net Sales $231,642   100.0% $238,266   100.0% $(6,624)  -2.8% $227,829   100.0% $238,250   100.0% $(10,421)  -4.4%
Internet Sales $165,473   71.4% $162,803   68.3% $2,670   1.6% $175,984   77.2% $178,758   75.0% $(2,774)  -1.6%
Contact Center Sales $66,169   28.6% $75,463   31.7% $(9,294)  -12.3% $51,845   22.8% $59,492   25.0% $(7,647)  -12.9%
Total Net Sales $231,642   100.0% $238,266   100.0% $(6,624)  -2.8% $227,829   100.0% $238,250   100.0% $(10,421)  -4.4%
 
Sales may be adversely affected in fiscal 20122014 due to increased competition and consumers giving more consideration to price and trading down to less expensive brands, including generics, some of which we may not carry.generics.  In response to these trends, the Company implemented a more aggressive pricing strategywill focus on advertising efficiency to improve new order sales and shifting sales to higher margin items, including generics, combined with increased advertising while continuing to expandexpanding our product offerings into pet supplies.  This more aggressive pricing strategy will result in a decrease to gross profit margins, and noofferings.  No guarantees can be made that the Company’s efforts will be successful, or that sales will grow in the future.
The majority of our product sales arewere affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications.  For the quarters ended June 30, September 30, December 31, and March 31 of fiscal 2011,Fiscal 2013, the Company’s sales were approximately 32%30%, 26%, 20%22%, and 22%, respectively.  For the quarters ended June 30, September 30, December 31, and March 31 of Fiscal 2012, the Company’s sales were approximately 31%, 24%, 21%, and 24%, respectively.  Sales in the March quarter of fiscal 2013 were negatively impacted by the colder than normal weather compared to the warmer than normal weather in the March quarter of fiscal 2012.

Cost of sales

Cost of sales increaseddecreased by $1.3$7.4 million, or 0.9%4.7%, to $147.7$150.7 million for the fiscal year ended March 31, 2011,2013, from $146.4$158.1 million for the fiscal year ended March 31, 2010.2012.  The increasedecrease in cost of sales is directly related to increased product costs.decreased sales.  As a percentage of sales, cost of sales was 63.8%66.1% in fiscal 2011,2013, as compared to 61.4%66.3% in fiscal 2010.2012.  The cost of sales percentage increasedecrease can be mainly attributedrelated to more aggressive sales promotions, reduceda change in product retail pricing, and increases in our product costs.mix to lower cost items, which includes generics.

Gross profit

Gross profit decreased by $7.9$3.1 million, or 8.6%3.8%, to $84.0$77.1 million for the fiscal year ended March 31, 2011,2013, from $91.9$80.2 million for the fiscal year ended March 31, 2010.2012.  Gross profit as a percentage of sales for fiscal 2011 and 20102013 was 36.2% and 38.6%33.9% compared to 33.7%, respectively.for fiscal 2012.  The gross profit percentage decreaseincrease can be mainly attributed to more aggressive sales promotions, reduceda change in product retail pricing, and increases in our product costs.mix to higher margin items, which includes generics.

General and administrative expenses
 
General and administrative expenses decreased by $141,000,$771,000, or 0.6%3.4%, to $22.2$21.6 million for the fiscal year ended March 31, 20112013 from $22.3$22.4 million for the fiscal year ended March 31, 2010.2012.  The decrease in general and administrative expenses for the fiscal year ended March 31, 20112013 was primarily due to the following: a $153,000$543,000 decrease in insurance expenses,bank service fees due to a reduction in insurance premiums;credit card fees; a $78,000 decrease to licenses and fees, due$293,000 reduction in payroll expenses related primarily to a one-time charge recognizeddecrease in fiscal 2010;stock compensation expense; a $147,000 decrease in professional fees, with the majority of the decrease relating to legal and accounting fees; and a $58,000 net$95,000 decrease in other expenses, including telephone expenses, travel expense, bank service fees, payroll expenses, and office expenses.  Offsetting the decrease was a $60,000 increase in professional fees, which includes investor relations and pharmacy fees; a $58,000an $111,000 increase in property expenses related to our website, an $110,000 increase in licenses and a $30,000fees, and an $86,000 net increase to bad debtin other expenses including office expense and insurance expense.  General and administrative expenses as a percentage of sales was 9.6%9.5% compared to 9.4% for the fiscal years ended March 31, 20112013 and 2010,2012, respectively.  The increase in general and administrative expenses as a percentage of sales can mainly be attributed to a reduction in sales in fiscal 2011.
20

2013.
 
Advertising expenses

Advertising expenses decreased by approximately $300,000,$3.0 million, or 1.1%9.7%, to approximately $27.4 million for the year ended March 31, 2011,2013, from approximately $27.7$30.4 million for the year ended March 31, 2010.2012.  The decrease in advertising expenses for fiscal 20112013 can be mainly attributed to a reduction inreduced advertising due to the unavailability of television remnant space inventory at prices the Company was willing to pay.inventory.  The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, increasedwas $44 for the fiscal year ended March 31, 2013, compared to $42 for the fiscal year ended March 31, 2011, compared to $34 for the year ended March 31, 2010.2012.  Advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, increased advertising spending, and price competition.
Historically, the advertising environment fluctuates due to supply and demand.  A more favorable advertising environment may positively impact future new order sales, whereas a less favorable advertising environment may negatively impact future new order sales.  As a percentage of sales, advertising expense was 11.812.0 % and 11.6%12.8% for the fiscal years ended March 31, 20112013 and 2010,2012, respectively.  The increasedecrease in advertising expense as a percentage of total sales for the fiscal year ended March 31, 20112013 can be attributed to decreased sales and increased new customer acquisition costs due to a reduction in response rates, as a resultadvertising expense, due to the unavailability of increased competition and softer demand.television remnant space inventory.  The Company currently anticipates advertising as a percentage of sales to be approximately 13% for fiscal 2012.2014.  However, the advertising percentage will fluctuate quarter to quarter due to seasonality and advertising availability.  For the fiscal year ended March 31, 2011,2013, quarterly advertising expenses as a percentage of sales ranged between 10%9% and 14%.

Depreciation

Depreciation increaseddecreased by approximately $54,000, or 4.1%,$320,000, to approximately $1.4 for the year ended March 31, 2011, from approximately $1.3$1.1 million for the year ended March 31, 2010.2013, from approximately $1.4 million for the year ended March 31, 2012.  This increasedecrease to depreciation for the year ended March 31, 20112013 can be attributed to an increasea reduction in new property and equipment additions, relating to the warehouse, pharmacy, and customer call center over the past 2 fiscal years.an increase in fully depreciated fixed assets.

Other income

Other income increaseddecreased by approximately $53,000,$48,000, to approximately $253,000$301,000 for the year ended March 31, 20112013 from approximately $200,000$349,000 for the year ended March 31, 2010.2012.  The increasedecrease to other income for the year ended March 31, 20112013 can be attributed to increased interesta reduction in advertising income.  Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $17.7$10.2 million remaining as of March 31, 2011,2013, on any quarterly dividend payment, or on its operating activities.

Provision for income taxes

For the fiscal years ended March 31, 20112013 and 2010,2012, the Company recorded an income tax provision for approximately $12.4$10.1 million and $14.7$9.7 million, respectively.  The effective tax rate for the fiscal years ended March 31, 20112013 and 20102012 were 37.3%37.1% and 36.2%36.8%, respectively.  The effective tax rate increase for the fiscal year ended March 31, 20112013, was attributeddue to a one-time $280,000charge related to a fiscal 2012 income tax charge to reconcile the remaining net operating loss carryforwardunder-accrual, which was recognized in the first quarter of fiscal 2011.ended December 31, 2012.  The Company estimates its effective tax rate will be approximately 37.0% for fiscal 2012.2014.

Net income

Net income decreasedincreased by approximately $5.1 million,$506,000, or 19.7%3.0%, to approximately $20.9$17.2 million for the fiscal year ended March 31, 20112013 from approximately $26.0$16.7 million for the fiscal year ended March 31, 2010.2012.  The increase was primarily due to a decrease was mainly attributable to the reductionin operating expenses offset by a decrease in gross profit margin and new order sales in fiscal 2011.2013.
21


Liquidity and Capital Resources

The Company’s working capital at March 31, 20122014 and 20112013 was approximately $78.2$66.1 million and approximately $80.6$59.8 million, respectively.  The $2.4$6.3 million decreaseincrease in working capital was primarily attributable to share repurchases and dividends paid during fiscal 2012, offset by cash flow generated from operations, and a decrease in long term investments.offset by dividends paid.  Net cash provided by operating activities was $20.4$13.5 million and $30.1$13.3 million for the fiscal years ended March 31, 20122014 and 2011,2013, respectively.  Net cash used in investing activities was $129,000 and $5.8 million for the years ended March 31, 2014 and 2013, respectively.  This change can be mainly attributed to an increase inthe purchasing of the Company’s inventory balance due to buying opportunities during fiscal 2012, compared to a more significant decrease in the Company’s inventory balance for fiscal 2011, along with a reduction in net income for fiscal 2012.  Net cash provided by investing activities was $11.6 million for the year ended March 31, 2012, compared to net cash used in investing activities of $10.8 million for the year ended March 31, 2011.  This change can be attributed to a decrease in the Company’s longshort term investments during fiscal 2012.2013, compared to no investments purchased during fiscal 2014.  Net cash used in financing activities was $34.9$13.2 million and $22.8$36.1 million for the years ended March 31, 20122014 and 2011,2013, respectively.  This change was primarily due to the Company paying $32.0 million in dividends in fiscal 2013, compared to $13.3 million in dividends in fiscal 2014.  This change was also due to the Company repurchasing approximately 2.1 million397,000 shares of its common stock for approximately $23.7 million for fiscal 2012, compared to the Company repurchasing 791,000 shares of its common stock for approximately $12.2$3.9 million in fiscal 2011.  For the years ended March 31, 2012 and 2011 the Company paid approximately $10.9 million and $10.7 million2013, compared to no stock repurchases in dividends.fiscal 2014.  As of March 31, 20122014 the Company had approximately $14.0$10.2 million remaining under the Company’s share repurchase plan.
Subsequent to March 31, 2012,2014, the Company’s Board of Directors declared a $0.15$0.17 per share dividend on May 4, 2012.5, 2014.  The Board established a May 14, 201216, 2014 record date and a May 25, 201223, 2014 payment date.  Depending on future market conditions the Company may utilize its cash and cash equivalents on the remaining balance of its current share repurchase plan, on quarterly dividends, or on its operating activities.
The Company had liquidated its entire Auction Rate Security (“ARS”) balance, which was classified as long term investments in our financial statements, as of March 31, 2012.  In fiscal 2012, the Company recorded an unrealized recovery of $110,000 within accumulated other comprehensive gain (loss), based upon receiving full par value for these ARS.  In fiscal 2011, the fair value of ARS investments was based upon a valuation assessment by an outside third party, conducted in April 2011.  The Company recorded an unrealized impairment loss of $110,000, in fiscal 2011, within accumulated other comprehensive gain (loss), based upon an assessment of the fair value of these ARS.  The $110,000 impairment was recorded as temporary due to the fact that the Company had both the ability and intent to hold these securities until anticipated recovery or maturity.

As of both March 31, 20122014 and 20112013 the Company had no outstanding lease commitments except for the lease for its 65,300 square foot facility.  We are not currently bound by any long or short term agreements for the purchase or lease of capital expenditures.  Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any increase in our business.  To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future.  Presently, we have approximately $500,000$2.8 million forecasted for capital expenditures in fiscal 20132015 which will be funded through cash from operations.  The Company’s primary source of working capital is cash from operations.  The Company presently has no need for alternative sources of working capital, and has no commitments or plans to obtain additional capital.

Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements as of March 31, 2012.2014.

Contractual Obligations and Commitments (In thousands)
 
      Less than        More than 
   Total  1 year  1-2 years  3-5 Years  5 years 
                 
 Property lease $2,478  $767  $784  $927  $- 
 Executive employment contract $550  $550  $-  $-  $- 
                      
 Total obligations $3,028  $1,317  $784  $927  $- 
     Less than        More than 
  Total  1 year  1-2 years  3-5 Years  5 years 
                
Property lease $2,175  $794  $796  $585  $- 
Executive employment contract $1,100  $550  $550  $-  $- 
                     
Total obligations $3,275  $1,344  $1,346  $585  $- 
 
Recent Accounting Pronouncements

The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

22

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices.  Our financial instruments include cash and cash equivalents, short term investments, accounts receivable, and accounts payable.  The book values of cash equivalents, short term investments, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments.  Interest rates affect our return on excess cash and investments.  As of March 31, 2012,2014, we had $46.8$18.3 million in cash and cash equivalents and $10.3$15.5 million in short term investments.  A majority of our cash and cash equivalents and investments generategenerates interest income based on prevailing interest rates.

A significant change in interest rates would impact the amount of interest income generated from our excess cash and investments.  It would also impact the market value of our investments.  Our investments are subject to market risk, primarily interest rate and credit risk.  Our investments are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors.  Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our investments to high-quality debt instruments with both short and long term maturities.  We do not hold any derivative financial instruments that could expose us to significant market risk.  At March 31, 2012,2014, we had no debt obligations.
 
23

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


  PETMED EXPRESS, INC. AND SUBSIDIARIES

  INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
  Page
   
Report of Independent Registered Public Accounting Firm 2524
   
Consolidated Balance Sheets as of March 31, 20122014 and 20112013 2625
   
Consolidated Statements of Comprehensive Income for each of the three years in the period ended March 31, 20122014 2726
   
Consolidated Statements of Changes in Shareholders’ Equity for each of the three years in the period ended March 31, 2012
2014
 2827
   
Consolidated Statements of Cash Flows for each of the three years in the period ended March 31, 20122014 2928
   
Notes to Consolidated Financial Statements 3029
   
Report of Management on Internal Control Over Financial Reporting 4239
   
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting 43
40
 
24

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Board of Directors and Shareholders
PetMed Express, Inc. and subsidiaries

We have audited the accompanying consolidated balance sheets of PetMed Express, Inc. and subsidiaries as of March 31, 20122014 and 2011,2013, and the related consolidated statements of comprehensive income, changes in shareholders’ equity and cash flows for each of the three years in the period ended March 31, 2012.2014.  These financial statements are the responsibility of the Company’sCompanys management.  Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the auditsaudit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of PetMed Express, Inc. and subsidiaries as of March 31, 20122014 and 2011,2013, and the results of their operations and their cash flows for each of the three years in the period ended March 31, 2012,2014, in conformity with U.S. generally accepted accounting principles. 

We have also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), PetMed Express, Inc. and subsidiaries’ internal control over financial reporting as of March 31, 2012,2014, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 1992, and our report dated May 29, 201227, 2014 expressed an unqualified opinion on the effectiveness of PetMed Express, Inc. and Subsidiaries’subsidiaries’ internal control over financial reporting.
/s/ McGladrey LLP 
McGladrey LLP
 
Fort Lauderdale, Florida
May 29, 2012

Fort Lauderdale, Florida
25

May 27, 2014
 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
PETMED EXPRESS, INC. AND SUBSIDIARIES 
CONSOLIDATED BALANCE SHEETS 
(In thousands) 
       
  March 31,  March 31, 
  2014  2013 
ASSETS      
       
Current assets:      
Cash and cash equivalents $18,305  $18,155 
Short term investments - available for sale  15,539   15,490 
Accounts receivable, less allowance for doubtful accounts of $7 and $5, respectively  1,761   1,439 
Inventories - finished goods  35,727   31,601 
Prepaid expenses and other current assets  1,761   1,090 
Deferred tax assets  1,062   982 
Prepaid income taxes  54   - 
Total current assets  74,209   68,757 
         
Nonurrent assets:        
Prepaid expenses  1,996   1,430 
Property and equipment, net  1,310   2,132 
Intangible assets  860   860 
         
Total assets $78,375  $73,179 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
         
Current liabilities:        
Accounts payable $5,768  $6,454 
Accrued expenses and other current liabilities  2,325   2,381 
Income taxes payable  -   162 
Total current liabilities  8,093   8,997 
         
Deferred tax liabilities  65   168 
         
Total liabilities:  8,158   9,165 
         
Commitments and contingencies        
         
Shareholders’ equity:        
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share  9   9 
Common stock, $.001 par value, 40,000 shares authorized; 20,190 and 21,109 shares issued and outstanding, respectively  20   20 
Additional paid-in capital  1,578   - 
Retained earnings  68,647   63,987 
Accumulated other comprehensive loss  (37)  (2)
         
Total shareholders’ equity  70,217   64,014 
         
Total liabilities and shareholders’ equity $78,375  $73,179 
 
  March 31,  March 31, 
  2012  2011 
       
  ASSETS      
       
Current assets:      
Cash and cash equivalents $46,801  $49,660 
Short term investments - available for sale  10,347   10,116 
Accounts receivable, less allowance for doubtful accounts of $5 and $6, respectively
  1,572   1,985 
Inventories - finished goods  26,217   25,140 
Prepaid expenses and other current assets  1,241   1,036 
Deferred tax assets  1,230   1,003 
Prepaid income taxes      199   664 
Total current assets  87,607   89,604 
         
Long term investments  -   12,390 
Property and equipment, net  2,597   3,433 
Intangible asset  860   860 
         
Total assets $91,064  $106,287 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
         
Current liabilities:        
Accounts payable $6,619  $6,452 
Accrued expenses and other current liabilities  2,772   2,509 
Total current liabilities  9,391   8,961 
         
Deferred tax liabilities  492   321 
         
Total liabilities:  9,883   9,282 
         
Commitments and contingencies        
         
Shareholders’ equity:        
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share
  9   9 
Common stock, $.001 par value, 40,000 shares authorized; 20,338 and 22,331 shares issued and outstanding, respectively
  20   22 
Retained earnings  81,108   97,115 
Accumulated other comprehensive gain (loss)  44   (141)
         
Total shareholders’ equity  81,181   97,005 
         
Total liabilities and shareholders’ equity $91,064  $106,287 
See accompanying notes to consolidated financial statements.
26

 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except for per share amounts)
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except for per share amounts)
          
  Year Ended March 31, 
  2014  2013  2012 
          
Sales $233,391  $227,829  $238,250 
Cost of sales  155,774   150,708   158,085 
             
Gross profit  77,617   77,121   80,165 
             
Operating expenses:            
General and administrative  21,352   21,592   22,363 
Advertising  27,180   27,433   30,369 
Depreciation  867   1,091   1,411 
Total operating expenses  49,399   50,116   54,143 
             
Income from operations  28,218   27,005   26,022 
             
Other income (expense):            
Interest income, net  185   306   288 
Other, net  (4)  (5)  61 
Total other income  181   301   349 
             
Income before provision for income taxes  28,399   27,306   26,371 
             
Provision for income taxes  10,427   10,141   9,712 
             
Net income $17,972  $17,165  $16,659 
             
Net change in unrealized gain (loss) on short and long term investments  (35)  (46)  185 
             
Comprehensive income $17,937  $17,119  $16,844 
             
Net income per common share:            
Basic $0.90  $0.86  $0.81 
Diluted $0.90  $0.86  $0.80 
             
Weighted average number of common shares outstanding:            
Basic  19,901   19,926   20,613 
Diluted  20,043   20,049   20,708 
             
Cash dividends declared per common share $0.66  $1.60  $0.53 
 
  Year Ended March 31, 
  2012  2011  2010 
          
Sales $238,250  $231,642  $238,266 
Cost of sales  158,085   147,686   146,405 
             
Gross profit  80,165   83,956   91,861 
             
Operating expenses:            
General and administrative  22,363   22,200   22,341 
Advertising  30,369   27,357   27,657 
Depreciation  1,411   1,375   1,321 
Total operating expenses  54,143   50,932   51,319 
             
Income from operations  26,022   33,024   40,542 
             
Other income (expense):            
Interest income, net  288   381   196 
Other, net  61   (128)  4 
Total other income  349   253   200 
             
Income before provision for income taxes  26,371   33,277   40,742 
             
Provision for income taxes  9,712   12,406   14,740 
             
Net income $16,659  $20,871  $26,002 
             
Net income per common share:            
Basic $0.81  $0.93  $1.15 
Diluted $0.80  $0.92  $1.14 
             
Weighted average number of common shares outstanding:            
Basic  20,613   22,514   22,617 
Diluted  20,708   22,643   22,746 
             
Cash dividends declared per common share $0.525  $0.475  $0.300 
See accompanying notes to consolidated financial statements.
27

 
PETMED EXPRESS, INC. AND SUBSIDIARIES
 CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
 Fiscal years ended March 31, 2010, March 31, 2011, and March 31, 2012
 (In thousands)
  Convertible  Common  Additional        Other    
  Preferred Stock  Stock  Paid-In  Retained  Treasury  Comprehensive    
  Shares  Amounts  Shares  Amounts  Capital  Earnings  Stock  Gain (Loss)  Total 
                            
Balance, March 31, 2009  3  $9   22,687  $23  $-  $75,156  $-  $(220) $74,968 
                                     
Issuance of common stock from exercise of stock options  -   -   102   -   735   -   -   -   735 
                                     
Issuance of restricted stock  -   -   201   -   -   -   -   -   - 
                                     
Share based compensation  -   -   -   -   1,594   -   -   -   1,594 
                                     
Tax benefit related to stock options exercised  -   -   -   -   299   -   -   -   299 
                                     
Dividends declared  -   -   -   -   -   (6,853)  -   -   (6,853)
                                     
Net income  -   -   -   -   -   26,002   -   26,002   26,002 
                                     
Other comprehensive loss:                                    
Net Change in unrealized gain on long term investments                              112   112 
                                     
Total comprehensive income                             $26,114   - 
                                     
Balance, March 31, 2010  3   9   22,990   23   2,628   94,305   -   (108)  96,857 
                                     
Issuance of common stock from exercise of stock options  -   -   46   -   340   -   -   -   340 
                                     
Issuance of restricted stock, net  -   -   86   -   -   -   -   -   - 
                                     
Share based compensation  -   -   -   -   2,171   -   - �� -   2,171 
                                     
Dividends declared  -   -   -   -   -   (10,822)  -   -   (10,822)
                                     
Repurchased and retired shares  -   -   (791)  (1)  (12,246)  -   -   -   (12,247)
                                     
Deferred tax adjustment related to resticted stock and stock options  -   -   -   -   (132)  -   -   -   (132)
                                     
Allocation of retirement of repurchased shares of additional paid in capital and retained earnings  -   -   -   -   7,239   (7,239)  -   -   - 
                                     
Net income  -   -   -   -   -   20,871   -   20,871   20,871 
                                     
Other comprehensive loss:                                    
Net Change in unrealized loss on short term investments                              (31)  (31)
Net Change in unrealized loss on long term investments                              (2)  (2)
                                     
Total comprehensive income                             $20,838   - 
                                     
Balance, March 31, 2011  3   9   22,331   22   -   97,115   -   (141)  97,005 
                                     
Issuance of restricted stock, net  -   -   91   -   -   -   -   -   - 
                                     
Share based compensation  -   -   -   -   2,246   -   -   -   2,246 
                                     
Dividends declared  -   -   -   -   -   (10,989)  -   -   (10,989)
                                     
Repurchased and retired shares  -   -   (2,084)  (2)  (23,683)  -   -   -   (23,685)
                                     
Deferred tax adjustment related to resticted stock  -   -   -   -   (240)  -   -   -   (240)
                                     
Allocation of retirement of repurchased shares of additional paid in capital and retained earnings  -   -   -   -   21,677   (21,677)  -   -   - 
                                     
Net income  -   -   -   -   -   16,659   -   16,659   16,659 
                                     
Other comprehensive gain:                                    
Net Change in unrealized gain on short term investments                              75   75 
Net Change in unrealized gain on long term investments                              110   110 
                                     
Total comprehensive income                             $16,844   - 
                                     
Balance, March 31, 2012  3  $9   20,338  $20  $-  $81,108  $-  $44  $81,181 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
Fiscal years ended March 31, 2012, March 31, 2013, and March 31, 2014
(In thousands)
                         
  Convertible  Common  Additional     Other    
  Preferred Stock  Stock  Paid-In  Retained  Comprehensive    
  Shares  Amounts  Shares  Amounts  Capital  Earnings  Gain (Loss)  Total 
                         
Balance, March 31, 2011  3  $9   22,331  $22  $-  $97,115  $(141) $97,005 
                                 
Issuance of restricted stock, net  -   -   91   -   -   -   -   - 
                                 
Share based compensation  -   -   -   -   2,246   -   -   2,246 
                                 
Dividends declared  -   -   -   -   -   (10,989)  -   (10,989)
                                 
Repurchased and retired shares  -   -   (2,084)  (2)  (23,683)  -   -   (23,685)
                                 
Deferred tax adjustment related to resticted stock  -   -   -   -   (240)  -   -   (240)
                                 
Allocation of retirement of repurchased shares of additional paid in capital and retained earnings  -   -   -   -   21,677   (21,677)  -   - 
                                 
Net income  -   -   -   -   -   16,659   16,659   16,659 
                                 
Other comprehensive gain:                                
Net Change in unrealized gain on short and long term investments                          185   185 
                                 
Total comprehensive income                         $16,844   - 
                                 
Balance, March 31, 2012  3   9   20,338   20   -   81,108   44   81,181 
                                 
Issuance of restricted stock, net  -   -   168   -   -   -   -   - 
                                 
Share based compensation  -   -   -   -   1,943   -   -   1,943 
                                 
Dividends declared  -   -   -   -   -   (32,080)  -   (32,080)
                                 
Repurchased and retired shares  -   -   (397)  -   (3,865)  -   -   (3,865)
                                 
Deferred tax adjustment related to resticted stock  -   -   -   -   (284)  -   -   (284)
                                 
Allocation of retirement of repurchased shares of additional paid in capital and retained earnings  -   -   -   -   2,206   (2,206)  -   - 
                                 
Net income  -   -   -   -   -   17,165   17,165   17,165 
                                 
Other comprehensive loss:                                
Net Change in unrealized loss on short term investments                          (46)  (46)
                                 
Total comprehensive income                         $17,119   - 
                                 
Balance, March 31, 2013  3   9   20,109   20   -   63,987   (2)  64,014 
                                 
Issuance of restricted stock, net  -   -   81   -   -   -   -   - 
                                 
Share based compensation  -   -   -   -   1,479   -   -   1,479 
                                 
Dividends declared  -   -   -   -   -   (13,312)  -   (13,312)
                                 
Deferred tax adjustment related to resticted stock  -   -   -   -   99   -   -   99 
                                 
Net income  -   -   -   -   -   17,972   17,972   17,972 
                                 
Other comprehensive loss:                                
Net Change in unrealized loss on short term investments                          (35)  (35)
                                 
Total comprehensive income                         $17,937   - 
                                 
Balance, March 31, 2014  3  $9   20,190  $20  $1,578  $68,647  $(37) $70,217 
 
See accompanying notes to consolidated financial statements.
28

 
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
          
  Year Ended 
  March 31, 
  2014  2013  2012 
Cash flows from operating activities:         
Net income $17,972  $17,165  $16,659 
Adjustments to reconcile net income to net cash provided by operating activities:            
Depreciation  867   1,091   1,411 
Share based compensation  1,479   1,943   2,246 
Deferred income taxes  (183)  (76)  (56)
Bad debt expense  95   56   47 
(Increase) decrease in operating assets and increase (decrease) in liabilities:            
Accounts receivable  (417)  77   366 
Inventories - finished goods  (4,126)  (5,384)  (1,077)
Prepaid income taxes  (54)  199   465 
Prepaid expenses and other current assets  (1,237)  (1,279)  (205)
Accounts payable  (686)  (165)  297 
Accrued expenses and other current liabilities  (42)  (499)  238 
Income taxes payable  (162)  162   - 
Net cash provided by operating activities  13,506   13,290   20,391 
             
Cash flows from investing activities:            
Net change in investments  (84)  (5,189)  12,344 
Purchases of property and equipment  (45)  (626)  (705)
Net cash provided by (used in) investing activities  (129)  (5,815)  11,639 
             
Cash flows from financing activities:            
Dividends paid  (13,326)  (31,972)  (10,964)
Purchases of treasury stock  -   (3,865)  (23,685)
Tax adjustment related to stock compensation  99   (284)  (240)
Net cash used in financing activities  (13,227)  (36,121)  (34,889)
             
Net increase (decrease) in cash and cash equivalents  150   (28,646)  (2,859)
Cash and cash equivalents, at beginning of year  18,155   46,801   49,660 
             
Cash and cash equivalents, at end of year $18,305  $18,155  $46,801 
             
Supplemental disclosure of cash flow information:            
             
Cash paid for income taxes $10,727  $10,140  $9,543 
             
Retirement of treasury stock $-  $3,865  $23,685 
             
Dividends payable in accrued expenses $262  $276  $168 
 
     Year Ended    
     March 31,    
  2012  2011  2010 
 Cash flows from operating activities:         
    Net income $16,659  $20,871  $26,002 
    Adjustments to reconcile net income to net cash provided by operating activities:            
        Depreciation  1,411   1,375   1,321 
        Share based compensation  2,246   2,171   1,594 
        Deferred income taxes  (56)  348   (305)
        Bad debt expense  47   48   18 
        (Increase) decrease in operating assets and increase (decrease) in liabilities:            
Accounts receivable  366   64   766 
Inventories - finished goods  (1,077)  3,924   (2,286)
Prepaid income taxes  465   (335)  32 
Prepaid expenses and other current assets  (205)  (426)  144 
Accounts payable  297   1,964   313 
Accrued expenses and other current liabilities  238   102   86 
 Net cash provided by operating activities  20,391   30,106   27,685 
             
 Cash flows from investing activities:            
    Net change in investments  12,344   (10,146)  2,150 
    Purchases of property and equipment  (705)  (667)  (1,047)
    Purchases of intangible asset  -   (10)  - 
 Net cash provided by (used in) investing activities  11,639   (10,823)  1,103 
             
 Cash flows from financing activities:            
    Dividends paid  (10,964)  (10,727)  (6,805)
    Purchases of treasury stock  (23,685)  (12,247)  - 
    Proceeds from the exercise of stock options  -   340   735 
    Tax benefit related to stock options exercised  -   -   299 
    Tax adjustment related to stock compensation  (240)  (132)  - 
 Net cash used in financing activities  (34,889)  (22,766)  (5,771)
             
 Net (decrease) increase in cash and cash equivalents  (2,859)  (3,483)  23,017 
 Cash and cash equivalents, at beginning of year  49,660   53,143   30,126 
             
 Cash and cash equivalents, at end of year $46,801  $49,660  $53,143 
             
 Supplemental disclosure of cash flow information:            
             
    Cash paid for income taxes $9,543  $12,578  $14,719 
             
    Retirement of treasury stock $23,685  $12,247  $- 
             
    Property and equipment purchases in accounts payable $-  $130  $418 
             
    Dividends payable in accrued expenses $168  $143  $48 
See accompanying notes to consolidated financial statements.
29

 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)           Summary of Significant Accounting Policies

Organization

PetMed Express, Inc. and subsidiaries, d/b/a 1-800-PetMeds (the “Company”), is a leading nationwide pet pharmacy.  The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer.  The Company markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the “1-800-PetMeds” brand name and “PetMeds” family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases.  The majority of all of the Company’s sales are to residents in the United States.  The Company’s executive offices are located in Pompano Beach, Florida.  The Company’s fiscal year end is March 31, and references herein to fiscal 2012, 2011,2014, 2013, or 20102012 refer to the Company’s fiscal years ended March 31, 2012, 2011,2014, 2013, and 2010,2012, respectively.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.  All significant intercompany transactions have been eliminated in consolidation.

Revenue Recognition

The Company generates revenue by selling pet medication products and pet supplies mainly to retail consumers.  The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the customer.  Outbound shipping and handling fees are included in sales and are billed upon shipment.  Shipping expenses are included in cost of sales.  The majority of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days.  Credit card sales minimize the accounts receivable balances relative to sales.  The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from the customers’ inability to make required payments, arising from either credit card charge-backs or insufficient funds checks.  The Company determines its estimates of the uncollectibility of accounts receivable by analyzing historical bad debts and current economic trends.  At March 31, 20122014 and 2011,2013, the allowance for doubtful accounts was approximately $5,000$7,000 and $6,000,$5,000, respectively.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.  Cash and cash equivalents at March 31, 20122014 and 20112013 consisted of the Company’s cash accounts and money market accounts with a maturity of three months or less.  The carrying amount of cash equivalents approximates fair value.  The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits.  The Company has not experienced any losses in such accounts.

Short and Long Term Investments

The Company’s short term investmentinvestments balance consists of short term bond mutual funds.  The Company’s long term investment balance consisted of auction rate securities (“ARS”), which are investments with contractual maturities generally between 20 to 30 years, in the form of municipal bonds and preferred stock, whose interest rates reset, typically every seven to twenty-eight days, through an auction process.  At the end of each reset period, investors can sell or continue to hold the securities at par.  Beginning in February 2008, auctions failed for the ARS held because sell orders exceeded buy orders.  These failures were not believed to be a credit issue, but rather are caused by a lack of liquidity.  The funds associated with these failed auctions were not accessible until the issuer calls the security, a successful auction occurs, a buyer is found outside of the auction process, or the security matures.
30

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1)Summary of Significant Accounting Policies (Continued)
As a result, these securities with failed auctions have been classified as long-term assets in the Consolidated Balance Sheet due to the fact that they were not currently trading at such date, and conditions in the general markets created uncertainty as to when successful auctions would be reestablished.  These ARS are recorded at estimated fair value and have variable interest rates that are recorded as interest income.  In accordance with ASC Topic 320 (“Accounting for Certain Investments in Debt and Equity Securities”), short term investments and long term investments are classifiedaccounted for as available-for-sale,available for sale securities with any changes in fair value to be reflected in other comprehensive income.income (loss).  The Company evaluates its longhad a short term investments for impairmentbalance of $15.5 million as of both March 31, 2014 and whether impairment is other-than-temporary, and, if other-than-temporary, then the measurement of the impairment loss is a charge to net income.  Unrealized gains and losses are deemed temporary and are included in accumulated other comprehensive income.  The Company recognized a temporary impairment on its ARS investments during fiscal 2011.  The Company did not believe that the underlying credit quality of the assets had been impacted; however the temporary impairment is mainly due to the lack of liquidity.  The Company liquidated its entire ARS balance in fiscal 2012.March 31, 2013.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)           Summary of Significant Accounting Policies (Continued)

Inventories

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or market value using a weighted average cost method.  The Company writes down its inventory for estimated obsolescence.  The inventory reserve was approximately $66,000$90,000 and $63,000$79,000 at March 31, 20122014 and 2011,2013, respectively.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets.  The furniture, fixtures, equipment, and computer software are depreciated over periods ranging from three to seven years.  Leasehold improvements and assets under capital lease agreements are amortized over the shorter of the underlying lease agreement or the useful life of the asset.

Long-lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.

Intangible AssetAssets

The intangible asset consists of a toll-free telephone number and an internet domain name.  In accordance with the ASC Topic 350 (“Goodwill and Other Intangible Assets”) the intangible assets are not being amortized, and are subject to an annual review for impairment.

Fair Value of Financial Instruments

The carrying amounts of the Company’s cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.
31

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1)           Summary of Significant Accounting Policies (Continued)

 
Advertising

The Company’s advertising expenses consist primarily of television advertising, online marketing, and direct mail/print advertising.  Television advertising costs are expensed as the advertisements are televised.  Internet costs are expensed in the month incurred and direct mail/print costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded.

Business Concentrations

The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers.  We have multiple suppliers for each of our products to obtain the lowest cost.  There were five suppliers from whom we purchased approximately 50% of all products in both fiscal 2014 and 2013.

Accounting for Share Based Compensation

The Company records compensation expense associated with stock options and restricted stock in accordance with ASC Topic 718 (Comprehensive Income“Share Based Payment”).  The Company adopted the modified prospective transition method provided under ASC Topic 718. The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)           Summary of Significant Accounting Policies (Continued)

Comprehensive Income

The Company applies ASC Topic 220 (“Reporting Comprehensive Income”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. The  At March 31, 2014 and 2013 the Company evaluatesrecorded an unrealized loss of $35,000 and $46,000 on its longshort term investments, for impairment and whether impairment is other-than-temporary, and measurement of an impairment loss as a charge to net income.  Unrealized gains and losses are deemed temporary and are included in accumulated other comprehensive income.respectively.  At March 31, 2012 the Company recorded an unrealized gain of $75,000 on its short term investments.  At March 31, 2012 the Company also recognized an unrealized recovery of $110,000, within accumulated other comprehensive income, based upon receiving full par value of these ARS.  At March 31, 2011 the Company recognized a temporary impairment on its ARS investments, and this unrealized loss was included in accumulated other comprehensive income.long term investments.

The following is a summary of our comprehensive income (in thousands):
 
  March 31, 
  2012  2011  2010 
          
Net income $16,659  $20,871  $26,002 
Net change in unrealized loss on short term investments
  75   (31)  - 
Net change in unrealized gain (loss) and redemptions on long term investments
  110   (2)  112 
Comprehensive income $16,844  $20,838  $26,114 
   March 31, 
   2014  2013  2012 
           
 Net income $17,972  $17,165  $16,659 
 Net change in unrealized gain (loss) on short term investments  (35)  (46)  75 
 Redemptions on long term investments  -   -   110 
 Comprehensive income $17,937  $17,119  $16,844 
 
Income Taxes

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities, and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.  The Company adopted the provisions of ASC Topic 740 ( “Accounting(“Accounting for Uncertainty in Income Taxes”, in the first quarter of fiscal 2008.  As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit.  For tax positions meeting the more-likely-than-not threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.  At the adoption date, the Company applied “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remained open.  The Company files tax returns in the U.S. federal jurisdiction and Florida and Georgia.  With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March 31, 2008.
32

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1)Summary of Significant Accounting Policies (Continued)
Upon implementing “Accounting for Uncertainty in Income Taxes” guidance, the Company did not recognize any additional liabilities for unrecognized tax positions.  The adoption of “Accounting for Uncertainty in Income Taxes” guidance had no material impact on the Company’s consolidated financial position, results of operations, or cash flows in fiscal 2012.2014.  Any interest and penalties related to income taxes will be recorded to other income (expenses).
Business Concentrations
The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers.  We have multiple suppliers for each of our products to obtain the lowest cost.  There were four suppliers from whom we purchased approximately 50% of all products in fiscal 2012, compared to seven suppliers from whom we purchased approximately 50% of all products in fiscal 2011.
Accounting for Share Based Compensation
The Company records compensation expense associated with stock options and restricted stock in accordance with ASC Topic 718 (“Share Based Payment”).  The Company adopted the modified prospective transition method provided under ASC Topic 718. The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.

Reclassifications

Certain reclassifications have been made to the prior years’ consolidated financial statements to conform to the fiscal 2014 presentation.  These reclassifications had no impact on net income, shareholders’ equity or cash flows as previously reported.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)           Summary of Significant Accounting Policies (Continued)

Recent Accounting Pronouncements

The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

(2)           Long Term Investments
The long term investment balances consisted of ARS investments.  Our ARS consisted of closed-end fund preferred ARS, with interest rates that reset, typically every seven to twenty-eight days. These ARS were rated AAA, the highest rating available by a rating agency. The fair value of our ARS investments was assessed by management with the assistance of an outside third party appraisal firm, during fiscal 2011.  At March 31, 2012, the Company had liquidated its entire Auction Rate Security (“ARS”) balance, and recorded an unrealized recovery of $110,000 within accumulated other comprehensive gain (loss) account, based upon receiving full par value for these ARS.   As of March 31, 2011, the Company held $12.5 million in ARS, at par, which were classified as long term investments and the Company recorded an unrealized impairment loss of approximately $2,000 for the year then ended.  As of March 31, 2011, cumulative losses of $110,000 were recognized within the accumulated other comprehensive loss account.  The $110,000 impairment was recorded as temporary due to the fact that the Company had the intent and the ability to hold these securities until anticipated recovery or maturity, and did expect to fully recover the cost basis of the investment.
(3)           Fair Value Measurements

Effective April 1, 2008, theThe Company adopted ASC Topic 820 (“Fair Value Measurements”), except as it applies to non-financialcarries various assets and non-financial liabilities subject to ASC Topic 320.  ASC Topic 320 clarifies thatat fair value in the Consolidated Balance Sheets.  Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  ASC Topic 820 (“Fair Value Measurements”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.
Level 3 - Unobservable inputs which are supported by little or no market activity.
33

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(3)           Fair Value Measurements (Continued)

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s cash equivalents and short term investments are classified within Level 1, with the exception of the investments in ARS. The Company’s investments in ARS are classified within Level 3 because they are valued using a discounted cash flow model.  Some of the inputs to this model are unobservable in the market and are significant.
1.  Assets and liabilities measured at fair value are summarized below (in thousands):
 
     Fair Value Measurement at March 31, 2012 Using 
     Quoted Prices  Significant    
     in Active  Other  Significant 
     Markets for  Observable  Unobservable 
  March 31,  Identical Assets  Inputs  Inputs 
  2012  (Level 1)  (Level 2)  (Level 3) 
 Assets:            
Cash and Cash equivalents - money markets funds $46,801  $46,801  $-  $- 
Short term investments - bond mutual funds  10,347   10,347   -   - 
                 
  $57,148  $57,148  $-  $- 
The following table is a reconciliation of financial assets measured at fair value using unobservable inputs (Level 3) during the year ended March 31, 2012 (in thousands):
  Auction Rate Securities 
  Ended March 31, 
  2012  2011 
       
 Balance, beginning of year $12,390  $12,392 
Redemption of securities  (12,500)  - 
Recovery of valuation  110   - 
Total unrealized loss included in other comprehensive income  -   (2)
 Balance, end of year $-  $12,390 
Long term investments measured at fair value using Level 3 inputs are comprised of ARS. Although ARS would typically be measured using Level 2 inputs, the recent failure of auctions and the lack of market activity and liquidity required that these securities be measured using Level 3 inputs.  The Company’s ARS consisted of closed-end fund preferred ARS, with interest rates that reset, typically every seven to twenty-eight days. The fair value of our ARS investments was assessed by management with the assistance of an outside third party appraisal firm, which was conducted during fiscal 2011.  The fair value was calculated using a discounted cash flow valuation model.  The three inputs used in determining the fair values of the ARS were:
(1) Forecasted interest payments cash flows - In failed ARS auctions interest rates are set by the terms of the prospectus. For almost all of the securities the terms are a combination of two components: the determination of a base rate which is based on the maximum of two indexes, or a single index as defined in the prospectus. Base rates are adjusted through either a multiplication factor or an addition of a spread factor as defined in the prospectus which is dependent on the credit rating of the security.  Our ARS were rated AAA, the highest rating available by a rating agency.
34
      Fair Value Measurement at March 31, 2014 Using 
   
March 31,
2014
  
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
  
Significant
Other
Observable
Inputs
(Level 2)
  
Significant
Unobservable
Inputs
(Level 3)
 
 Assets:            
 Cash and Cash equivalents - money market funds $18,305  $18,305  $-  $- 
 Short term investments -bond mutual funds  15,539   15,539   -   - 
                  
   $33,844  $33,844  $-  $- 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(3)           Fair Value Measurements (Continued)
(2) Discount rate calculation - The discount rates were calculated from the applicable forward curve plus a credit risk/liquidity spread. The credit risk spread was estimated via the credit spreads for 1-3 year term, AAA rated, debt over US Treasury notes and bonds which were determined to be 50 basis points (0.50%).  To address the continued illiquidity of the Company’s ARS portfolio, an additional spread of 0.30% was added to the credit risk spread.  This spread is based on the required yield attributable to liquidity for AAA rated debt, as determined by empirical studies.  Specifically, research on municipal bond yields indicate that for AAA rated securities, the liquidity component represents approximately 7-10% of the required yield. In total, a credit risk/liquidity spread of 0.80% was utilized.
(3) A present value calculation was performed utilizing the cash flow of the forecasted interest payments combined with the discount rate determined above.
At March 31, 2012, the Company had liquidated its entire ARS balance, and recorded an unrealized recovery of $110,000 within accumulated other comprehensive gain (loss) account, based upon receiving full par value for these ARS.  As of March 31, 2011, the Company held $12.5 million in ARS, at par, which were classified as long term investments and the Company recorded an unrealized impairment loss of approximately $2,000 for the year then ended.  As of March 31, 2011, cumulative losses of $110,000 were recognized within the accumulated other comprehensive loss account, based upon an assessment by the outside third party appraisal firm.  The $110,000 impairment was recorded as temporary due to the fact that the Company had the intent and the ability to hold these securities until anticipated recovery or maturity, and did expect to fully recover the cost basis of the investment.
(4)           Property and Equipment

Major classifications of property and equipment consist of the following (in thousands):

  March 31, 
  2012  2011 
       
Leasehold improvements $1,092  $1,063 
Computer software  2,406   2,236 
Furniture, fixtures and equipment  5,475   5,194 
   8,973   8,493 
Less: accumulated depreciation  (6,376)  (5,060)
         
Property and equipment, net $2,597  $3,433 
   March 31, 
   2014  2013 
 Leasehold improvements $1,124  $1,116 
 Computer software  2,749   2,735 
 Furniture, fixtures and equipment  5,771   5,748 
    9,644   9,599 
 Less: accumulated depreciation  (8,334)  (7,467)
          
 Property and equipment, net $1,310  $2,132 
 
(5)NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(4)           Accrued Expenses and Other Current Liabilities

Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):
 
  March 31, 
  2012  2011 
       
Accrued sales tax $499  $505 
Accrued credit card fees  323   421 
Accrued salaries and benefits  569   475 
Accrued professional expenses  319   185 
Accrued advertising expenses  230   196 
Accrued sales return allowance  167   155 
Accrued dividends payable  168   143 
Other accrued liabilities  497   429 
         
Accrued expenses and other current liabilities $2,772  $2,509 
   March 31, 
   2014  2013 
          
 Accrued sales tax $478  $473 
 Accrued credit card fees  275   269 
 Accrued salaries and benefits  754   899 
 Accrued professional expenses  275   225 
 Accrued sales return allowance  143   138 
 Accrued dividends payable  262   276 
 Other accrued liabilities  138   101 
          
 Accrued expenses and other current liabilities $2,325  $2,381 
(5)           Net Income Per Share

In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method.  Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding.

The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):
 
35
   Year Ended March 31, 
   2014  2013  2012 
           
 Net income (numerator):         
 Net income $17,972  $17,165  $16,659 
 Shares (denominator)            
 
Weighted average number of common shares outstanding used in basic computation
  19,901   19,926   20,613 
 
Common shares issuable upon the vesting of restricted stock
  132   113   85 
 
Common shares issuable upon conversion of preferred shares
  10   10   10 
 Shares used in diluted computation  20,043   20,049   20,708 
 Net income per common share:            
 Basic $0.90  $0.86  $0.81 
 Diluted $0.90  $0.86  $0.80 


At March 31, 2014 and 2013, all restricted stock was included in the diluted net income per common share computation.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
(6)           Income Taxes
 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):
 
 March 31,  March 31, 
 2012  2011  2014  2013 
Deferred tax assets:            
Bad debt and inventory reserves $26  $25 
Accrued expenses  535   543   679   608 
Deferred stock compensation  331   336   248   244 
Net operating loss carryforward  250   349   53   152 
        
Deferred tax assets  1,142   1,253 
Less: valuation allowance  -   - 
Bad debt and inventory reserves  35   31 
                
Total deferred tax assets  1,142   1,253   1,015   1,035 
                
Deferred tax liabilities:                
Property and equipment  (404)  (571)  (18)  (221)
        
Total net deferred taxes $738  $682  $997  $814 
 
There was no change in the valuation allowance which was $0 for both the fiscal years ended March 31, 2012 and 2011.  At March 31, 2012,2014, the Company had federal net operating loss carryforwards of approximately $675,000.$142,000.  The federal net operating loss carryforwards expire in the years 2020 and 2021.year 2020.  The use of such net operating loss carryforwards is limited to approximately $266,000 annually due to a change of control on November 22, 2000.
The components of the income tax provision consist of the following (in thousands):
 
 Year Ended March 31,  Year Ended March 31, 
 2012  2011  2010  2014  2013  2012 
                  
Current taxes                  
Federal $9,138  $11,007  $13,738  $9,689  $9,588  $9,138 
State  870   1,052   1,307   921   913   870 
Total current taxes  10,008   12,059   15,045   10,610   10,501   10,008 
                        
Deferred taxes                        
Federal  (270)  317   (279)  (167)  (329)  (270)
State  (26)  30   (26)  (16)  (31)  (26)
Total deferred taxes  (296)  347   (305)  (183)  (360)  (296)
                        
Total provision for income taxes $9,712  $12,406  $14,740  $10,427  $10,141  $9,712 
 
The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):
 
  Year Ended March 31, 
  2012  2011  2010 
          
Income taxes at U.S. statutory rates $9,230  $11,647  $14,260 
State income taxes, net of federal tax benefit  540   714   823 
Permanent differences  (68)  (64)  (123)
Other  10   109   113 
Change in valuation allowance  -   -   (333)
             
Total provision for income taxes $9,712  $12,406  $14,740 
36

  Year Ended March 31, 
  2014  2013  2012 
          
Income taxes at U.S. statutory rates $9,940  $9,557  $9,230 
State income taxes, net of federal tax benefit  583   562   540 
Permanent differences  (35)  (74)  (68)
Other  (61)  96   10 
Total provision for income taxes $10,427  $10,141  $9,712 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
(7)           Shareholders’ Equity
 
Preferred Stock
 
In April 1998, the Company issued 250,000 shares of its $.001 par value preferred stock at a price of $4.00 per share, less issuance costs of $112,187.  Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder.  The shares have a liquidation value of $4.00 per share and may pay dividends at the sole discretion of the Company.  The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future.  Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company.  As of March 31, 20122014 and 2011,2013, 2,500 shares of the convertible preferred stock remained unconverted and outstanding.
 
Share Repurchase Plan
 
On November 8, 2006, the Company’sCompanys Board of Directors approved a share repurchase plan of up to $20.0 million.  On October 31, 2008, November 1, 2010, and August 1, 2011, the Company’s Board of Directors approved a second, third, and fourth share repurchase plan, respectively, each for an additional $20.0 million.  The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company’sCompanys discretion, subject to market conditions and other factors, in accordance with Securities and Exchange Commission requirements.  There can be no assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company may discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements.  Shares purchased pursuant to the share repurchase plan will either be cancelled or held in the Company’sCompanys treasury.  During fiscal 20122013 the Company repurchased approximately 2.1 million397,000 shares of the Company’s outstanding common stock for approximately $23.7$3.9 million, averaging approximately $11.36$9.74 per share.  During fiscal 20112014 the Company repurchased approximately 791,000 shares of the Company’s outstanding common stock for approximately $12.2 million, averaging approximately $15.47 per share.had no share repurchases.  As of March 31, 20122014 the Company had approximately $14.0$10.2 million remaining under the Company’s share repurchase plan.
 
Dividends
 
On August 3, 2009, the Company’s Board of Directors declared its first quarterly dividend of $0.10 per share on its common stock.  On August 2, 2010, the Company’s Board of Directors increased the quarterly dividend to $0.125 per share, and then on January 27, 2012, the Company’s Board of Directors increased the quarterly dividend to $0.15 per share.  On December 3, 2012, the Company’s Board of Directors declared a special dividend of $1.00 per share on its common stock.  On July 26, 2013, the Company’s Board of Directors increased the quarterly dividend to $0.17 per share.  The Company intends to continue to pay regular quarterly dividends; however the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.
 
During fiscal 2012,2014, our Board of Directors declared the following dividends:
 
Declaration Date Per Share
Dividend
 Record Date Total Amount
(In thousands)
 Payment Date
         
May 6, 2011 $0.125 May 16, 2011 $2,782 May 27, 2011
July 29, 2011 $0.125 August 12, 2011 $2,626 August 26, 2011
October 28, 2011 $0.125 November 11, 2011 $2,542 November 25, 2011
January 27, 2012 $0.150 February 10, 2012 $3,051 February 24, 2012
37

Declaration Date 
Per Share
Dividend
 Record Date 
Total Amount
(In thousands)
 Payment Date
         
May 3, 2013 $0.150 May 15, 2013 $3,016 May 24, 2013
July 26, 2013 $0.170 August 12, 2013 $3,433 August 23, 2013
October 28, 2013 $0.170 November 8, 2013 $3,432 November 22, 2013
January 30, 2014 $0.170 February 12, 2014 $3,432 February 21, 2014
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
(8)           Stock Options and Restricted Stock
The PetMed Express, Inc. 1998 Stock Option Plan (the “Plan”), which expired on July 31, 2008, provided for the issuance of qualified options to officers and key employees, and nonqualified options to directors, consultants, and other service providers, to purchase the Company’s common stock.  The Company had reserved 5.0 million shares of common stock for issuance under the Plan.  The exercise prices of options issued under the Plan must be equal to or greater than the market price of the Company’s common stock as of the date of issuance.  Options generally vest ratably over a three-year period commencing on the first anniversary of the grant with respect to options granted to employees/directors under the Plan.  The Company had no options outstanding at March 31, 2012 and 2011.  No options have been issued since May 2005.  Cash received from stock options exercised for the fiscal years ended March 31, 2012, 2011, and 2010 was approximately $0, $340,000 and $735,000, respectively.  The income tax benefits from stock options exercised totaled approximately $0, $0, and $299,000, for the fiscal years ended March 31, 2012, 2011, and 2010, respectively.  At March 31, 2012 and 2011, there were no exercisable stock options.  As of March 31, 2012 and 2011 the Company had no non-vested stock options.  As of March 31, 2012 and 2011, there was no unrecognized compensation expense, aggregate intrinsic value, or weighted average remaining term, related to vested stock option awards.
 
On July 28, 2006, the Company received shareholder approval for the adoption of the 2006 Employee Equity Compensation Restricted Stock Plan (the “Employee Plan”) and the 2006 Outside Director Equity Compensation Restricted Stock Plan (the “Director Plan”).  The purpose of the plans is to promote the interests of the Company by securing and retaining both employees and outside directors.  The Company hashad reserved 1.0 million shares of common stock for issuance under the Employee Plan, and 200,000 shares of common stock for issuance under the Director Plan.  In July 2012 the Company received shareholder approval to ratify the amendment to the Company’s Director Plan passed by the Board of Directors to increase the number of shares available for issuance under the Director Plan from 200,000 to 400,000.  Additionally, the Company received shareholder approval to ratify the amendment passed by the Board of Directors to provide for a 10% automatic increase every year in the amount of shares available for issuance under each of the plans.  The value of the restricted stock is determined based on the market value of the stock at the issuance date.  The restriction period or forfeiture period is determined by the Company’s Board and is to be no less than 1 year and no more than ten years.  The Company had 542,377731,627 restricted common shares issued under the Employee Plan and 152,000212,000 restricted common shares issued under the Director Plan at March 31, 2012,2014, all shares of which were issued subject to a restriction or forfeiture period which will lapse ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over the three-year restriction period.  For each of the years ended March 31, 20122014 and 2011,2013, the Company recognized $2.2 million of compensation expense related to the Employee and Director Plans.Plans of $1.5 million and $1.9 million, respectively.
 
A summary of the Company’s non-vested restricted stock as of March 31, 20122014 is as follows:
 
  
Employee
Plan
Number of
Shares (In
thousands)
  Director
Plan
Number of
Shares (In
thousands)
  Total Plans
Number of
Shares (In
thousands)
 
          
Non-vested restricted stock outstanding at March 31, 2011  196   54   250 
             
Restricted stock granted  61   30   91 
             
Restricted stock vested  (96)  (26)  (122)
             
Restricted stock forfeited or expired  -   -   - 
             
Non-vested Restricted stock outstanding at March 31, 2012  161   58   219 
  
Employee
Plan
Number of Shares (In thousands)
  
Director
Plan
Number of Shares (In thousands)
  Both Plans Number of Shares (In thousands) 
          
Non-vested restricted stock outstanding at March 31, 2013  200   60   260 
             
Restricted stock granted  53   30   83 
             
Restricted stock vested  (82)  (30)  (112)
             
Restricted stock forfeited or expired  (1)  -   (1)
             
Non-vested restricted stock outstanding at March 31, 2014  170   60   230 
 
At March 31, 20122014 and 2011,2013, there were 218,757229,558 and 249,755260,389 non-vested restricted stock shares outstanding, respectively.  During the fiscal years ended March 31, 20122014 and 2011,2013, the Company issued, net of forfeitures, 91,15081,500 and 86,584167,750 restricted shares, respectively.  At March 31, 20122014 and 2011,2013, there were $2.5 million and $3.7$2.6 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the remaining weighted average vesting period of 1.62.0 years and 2.5 years for both fiscal 20122014 and 2011.
38

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(9)           Net Income Per Share2013, respectively.
 
In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted net income per common share includes the dilutive effect of potential restricted stock and stock options exercised and the effects of the potential conversion of preferred shares, calculated using the treasury stock method.  Outstanding stock options, restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding.
The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):
  Year Ended March 31, 
  2012  2011  2010 
          
Net income (numerator):         
          
Net income $16,659  $20,871  $26,002 
             
Shares (denominator)            
             
Weighted average number of common shares outstanding used in basic computation  20,613   22,514   22,617 
Common shares issuable upon exercise of stock options and vesting of restricted stock  85   119   119 
Common shares issuable upon conversion of preferred shares  10   10   10 
Shares used in diluted computation  20,708   22,643   22,746 
             
Net income per common share:            
             
Basic $0.81  $0.93  $1.15 
Diluted $0.80  $0.92  $1.14 
At March 31, 2012 and 2011, all common stock options and restricted stock were included in the diluted net income per common share computation as their exercise prices were less than the average market price of the common shares for the period.
 (10) (9)          Valuation and Qualifying Accounts
 
Activity in the Company’sCompanys valuation and qualifying accounts consists of the following (in thousands):
 
  Year Ended March 31, 
  2012  2011  2010 
          
Allowance for doubtful accounts:         
Balance at beginning of period $6  $5  $59 
Provision for doubtful accounts  47   48   17 
Write-off of uncollectible accounts receivable  (48)  (47)  (71)
             
Balance at end of year $5  $6  $5 
             
Valuation allowance for deferred tax assets:            
Balance at beginning of period $-  $-  $333 
Reductions  -   -   (333)
             
Balance at end of year $-  $-  $- 
39

  Year Ended March 31, 
  2014  2013  2012 
          
Allowance for doubtful accounts:         
   Balance at beginning of period $5  $5  $6 
   Provision for doubtful accounts  95   56   47 
   Write-off of uncollectible accounts receivable  (93)  (56)  (48)
             
   Balance at end of year $7  $5  $5 
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
(11)(10)        Commitments and Contingencies
 
Legal Matters and Routine Proceedings
In October 2009, the Company was notified that it was named as a defendant in a multi-defendant lawsuit, filed in the United States District Court for the Eastern District of Texas, Marshall Division, seeking declaratory, injunctive, and monetary relief styled Charles E. Hill & Associates, Inc. v. ABT Electronics, Inc., et al, Cause No. 2:09-CV-313.  The lawsuit alleges that the Company is infringing on patents related to electronic catalog systems.  From the outset, the vendor that provides the Company with the Internet software had been defending and indemnifying the Company.  However, effective February 15, 2011, the company that acquired this vendor declined to provide any further indemnification of the Company.  On October 5, 2011, the parties engaged in court-ordered mediation, which was unsuccessful.  Without admitting any liability or wrongdoing, and with no finding or admission as to the merit or lack of merit of any claim or defense asserted in connection with the litigation, in May 2012, the Company entered into a licensing agreement, for a confidential amount, and a Stipulation of Dismissal was filed with the Court, dismissing the lawsuit against the Company.
 
The Company has settled complaints that had been filed with various states’ pharmacy boards in the past.  There can be no assurances made that other states will not attempt to take similar actions against the Company in the future.  The Company initiates litigation to protect its trade or service marks.  There can be no assurance that the Company will be successful in protecting its trade or service marks.  Legal costs related to the above matters are expensed as incurred.
 
Employment Agreements
 
On February 8, 2010,January 25, 2013, the Company amended the CEO’s existing Executive Employment Agreement of Menderes Akdag, the Company’s President, Chief Executive Officer, and Director, and entered into Amendment No. 34 to the Executive Employment Agreement with Mr. Akdag.  The Agreement amended certain provisions of the Executive Employment Agreement as follows: the term of the Agreement is for three years, commencing on March 16, 2010;2013; Mr. Akdag’s salary was increased toremained at $550,000 per year throughout the term of the Agreement, and Mr. Akdag was granted 120,000108,000 shares of restricted stock.  The restricted stock was granted on March 16, 2010,2013, in accordance with the Company’s 2006 Employee Equity Compensation Restricted Stock Plan and the restrictions shall lapse ratably over a three-year period, and as of March 31, 2012, there were 40,000 unvested shares of restricted stock.period.
 
Operating Lease
 
The Company leases its 65,300 square foot executive offices, warehouse facility, and customer service and pharmacy contact centers under a non-cancelable operating lease.  On January 29, 2010, the Company signed a sixth addendum to its existing lease extending the terms of the lease until May 31, 2015.  The Company is responsible for certain maintenance costs, taxes, and insurance under this lease.
The future minimum annual lease payments are as follows:
 
Years Ending March 31, (in thousands)        
        
2013  767  
2014  784  
2015  794  2015  794 
2016  133  2016  133 
          
Total lease payments $2,478  Total lease payments $927 
 
Rent expense was $745,000, $724,000,$785,000, $767,000, and $703,000$745,000 for the years ended March 31, 2012, 20112014, 2013 and 2010,2012, respectively.
 
40

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (12)(11)        Sales by Category
 
The following table provides a breakdown of the percentage of total sales by each category during the indicated periods:
 
 Year Ended March 31,  Year Ended March 31, 
 2012  2011  2010  2014  2013  2012 
                  
Non-prescription medications and supplies  59%  61%  64%  55%  59%  59%
Prescription medications  40%  38%  35%  44%  40%  40%
Shipping and handling charges and other  1%  1%  1%  1%  1%  1%
Total  100%  100%  100%  100%  100%  100%
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(12)Employee Benefit Plan
 
 (13)        Employee Benefit Plan
The Company maintains a 401(k) Savings Plan for eligible employees.  The plan is a defined contribution plan that is administered by the Company.  All regular, full-time employees are eligible for voluntary participation upon completing one year of service and having attained the age of 21.  The plan provides for growth in savings through contributions and income from investments.  It is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended.  Plan participants are allowed to contribute a specified percentage of their base salary.  In 2006, the Company adopted a matching plan which is funded subsequent to the calendar year.  During the fiscal years ended March 31, 20122014 and 2011,2013, the Company charged $165,000$181,000 and $168,000,$173,000, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.
 
(14)(13)Quarterly Financial Data (Unaudited)
 
Summarized unaudited quarterly financial data for fiscal 20122014 and 20112013 is as follows (in thousands, except for per share amounts):
Quarter Ended: June 30, 2011  September 30, 2011  December 31, 2011  March 31, 2012 
             
Sales $73,578  $58,225  $50,523  $55,924 
Gross Profit $24,110  $19,934  $17,154  $18,967 
Income from operations $7,565  $6,080  $6,102  $6,275 
Net income $4,837  $3,930  $3,898  $3,993 
Diluted net income per common share $0.22  $0.19  $0.19  $0.20 
                 
Quarter Ended: June 30, 2010  September 30, 2010  December 31, 2010  March 31, 2011 
                 
Sales $74,369  $61,245  $45,118  $50,910 
Gross Profit $27,226  $22,330  $16,925  $17,475 
Income from operations $11,827  $7,727  $7,027  $6,443 
Net income $7,225  $4,977  $4,522  $4,147 
Diluted net income per common share $0.32  $0.22  $0.20  $0.19 
              
 
Quarter Ended:
 June 30, 2013  September 30, 2013  December 31, 2013  March 31, 2014 
              
 Sales $74,194  $60,479  $50,086  $48,632 
 Gross Profit $24,013  $19,252  $16,889  $17,463 
 Income from operations $7,497  $6,532  $7,047  $7,142 
 Net income $4,755  $4,150  $4,541  $4,526 
 Diluted net income per common share $0.24  $0.21  $0.23  $0.23 
                  
Quarter Ended:
 June 30, 2012  September 30, 2012  December 31, 2012  March 31, 2013 
                  
 Sales $68,955  $58,145  $49,609  $51,120 
 Gross Profit $22,304  $19,370  $17,212  $18,235 
 Income from operations $6,204  $6,326  $7,209  $7,266 
 Net income $3,952  $4,034  $4,577  $4,602 
 Diluted net income per common share $0.20  $0.20  $0.23  $0.23 
 
(15)(14)Subsequent Events
 
On April 30, 2014, the Company entered into a seventh amendment of its operating lease to extend its existing lease until December 1, 2016.  On May 4, 2012,5, 2014, the Company’s Board of Directors declared a quarterly dividend of $0.15$0.17 per share on its common stock.  The $3.1$3.4 million dividend was paid on May 25, 2012,23, 2014, to shareholders of record at the close of business on May 14, 2012.16, 2014.
 
41

REPORT OF MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management of the Company is responsible for the preparation and integrity of the Consolidated Financial Statements appearing in our Annual Report on Form 10-K.  The financial statements were prepared in conformity with generally accepted accounting principles appropriate in the circumstances and, accordingly, include certain amounts based on our best judgments and estimates.  Financial information in the Annual Report on Form 10-K is consistent with that in the financial statements.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) under the Securities Exchange Act of 1934 (“Exchange Act”).  The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Consolidated Financial Statements.  Our internal control over financial reporting is supported by a team of consultants and appropriate reviews by management, written policies and guidelines, careful selection and training of qualified personnel, and a written Corporate Code of Business Conduct and Ethics adopted by our Company’s Board of Directors, applicable to all Company Directors and all officers and employees of our Company and subsidiaries.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements and even when determined to be effective, can only provide reasonable assurance with respect to financial statement preparation and presentation.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Audit Committee (“Committee”) of our Company’s Board of Directors, comprised solely of Directors who are independent in accordance with the requirements of The NASDAQ Stock Market LLC listing standards, the Exchange Act and the Company’s Corporate Governance Guidelines, meets with the independent auditors and management periodically to discuss internal control over financial reporting, and auditing and financial reporting matters.  The Committee reviews with the independent auditors the scope and results of the audit effort.  The Committee also meets periodically with the independent auditors without management present to ensure that the independent auditors have free access to the Committee.  Our Audit Committee’s Report can be found in the Company’s 20122014 Proxy Statement.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2012.2014.  In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework.  Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of March 31, 2012.2014.

The Company’s independent auditors, McGladrey LLP, a registered public accounting firm, are appointed by the Audit Committee of the Company’s Board of Directors, subject to ratification by our Company’s shareholders.  McGladrey LLP have audited and reported on the Consolidated Financial Statements of PetMed Express, Inc. and subsidiaries, and issued a report on the Company’s internal control over financial reporting.  The reports of the independent auditors are contained in our Annual Report on Form 10-K.
 
/s/ Menderes Akdag 
Menderes Akdag
President, Chief Executive Officer, President, Director
 
May 29, 201227, 2014
/s/ Bruce S. Rosenbloom 
Bruce S. Rosenbloom
Chief Financial Officer
 
May 29, 201227, 2014
 
42

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ON INTERNAL CONTROL OVER FINANCIAL REPORTING
TheTo the Board of Directors and StockholdersShareholders
PetMed Express, IncInc. and subsidiaries:

We have audited PetMed Express, Inc. and subsidiaries’ internal control over financial reporting as of March 31, 2012,2014, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).in 1992.  PetMed Express, Inc. and subsidiariessubsidiaries’ management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report of Management on Internal Control over Financial Reporting.  Our responsibility is to express an opinion on the company’scompanys internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audit also included performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinion.

A company’scompanys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company’scompanys internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’scompanys assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, PetMed Express, Inc. and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of March 31, 2012,2014, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.Commission in 1992.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements of PetMed Express, IncInc. and subsidiaries.subsidiaries and our report dated May 29, 201227, 2014 expressed an unqualified opinion.
 
/s/ McGladrey LLP 
McGladrey LLP
Fort Lauderdale, Florida
May 29, 2012
 
43Fort Lauderdale, Florida

May 27, 2014
 
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of March 31, 2012,2014, the end of the period covered by this report (the “Evaluation Date”Evaluation Date).  Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date, that our disclosure controls and procedures were effective such that the information relating to PetMed Express, Inc., including our consolidated subsidiaries, required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 20122014 based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control — Integrated Framework, our management concluded that the Company maintained effective internal control over financial reporting as of March 31, 2012,2014, as stated in our report which is included herein. Our internal control over financial reporting as of March 31, 20122014 has been audited by McGladrey LLP, an independent registered public accounting firm, as stated in their report which is included herein.

 
Changes in Internal Controls over Financial Reporting

There have been no changes in our internal controls over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

Not applicable.
44

 
PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2012,2014, relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 2012,25, 2014, and is incorporated herein by reference.

We adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.  The Company’s Code of Business Conduct and Ethics may be found in our 2004 Proxy which was filed on June 30, 2004.  You may also obtain a copy of our Code of Business Conduct and Ethics free of charge by contacting Investor Relations at 1-800-738-6337.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2012,2014, relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 2012,25, 2014, and is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this item (other than information required by Item 201(d) of Regulation S-K with respect to equity compensation plans, which is set forth under Item 5. in this Annual Report on Form 10-K) will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2012,2014, relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 2012,25, 2014, and is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2012,2014, relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 2012,25, 2014, and is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2012,2014, relating to our 20122014 Annual Meeting of Stockholders to be held on July 27, 2012,25, 2014, and is incorporated herein by reference.
 
45

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)  The following documents are filed as part of this report on Form 10-K.
(1) Consolidated Financial Statements
The following exhibits are filed as part of this report on Form 10-K.
(3) Articles of Incorporation and By-Laws
(a)The following documents are filed as part of this report on Form 10-K.
(1) Consolidated Financial Statements
The following exhibits are filed as part of this report on Form 10-K.
(3) Articles of Incorporation and By-Laws
 3.1Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).
 3.2By-Laws of the Corporation (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000)2000).
 (4) Instruments Defining the Rights of Security Holders
 4.1Specimen common stock certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).
(10) Material Contracts
(10) Material Contracts
 10.11998 Stock Option Plan incorporated by reference to Exhibit 10.1 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).
 10.2Employment Agreement with Menderes Akdag (incorporated by reference to Exhibit 10 of the Registrant’s Form 8-K filed March 30, 2001).
 10.3Agreement for the Sale and Leaseback of the Land and Building (incorporated by reference to Exhibit 99.1 of the Registrant’s Form 8-K filed June 14, 2001).
 10.4Amendment Number 1 to Executive Employment Agreement with Menderes Akdag (incorporated by reference to Exhibit 99.1 of the Registrant’s Form 8-K filed March 18, 2004).
 10.5Amendment Number 2 to Executive Employment Agreement with Menderes Akdag (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed February 28, 2007).
 10.62006 Employee Equity Compensation Restricted Stock Plan (incorporated by reference to our definitive Proxy Statement for our 2006 Annual Meeting of Stockholders filed June 22, 2006).
 10.72006 Outside Director Equity Compensation Restricted Stock Plan (incorporated by reference to our definitive Proxy Statement for our 2006 Annual Meeting of Stockholders filed June 22, 2006).
 10.8Employment Letter with Bruce Rosenbloom dated May 30, 2001 (incorporated by reference to Exhibit 10.9 of the Registrant’s Form 8-K filed April 7, 2009).
 10.9Amendment Number 3 to Executive Employment Agreement with Menderes Akdag (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed February 8, 2010).
(14) Corporate Code of Ethics
10.10Amendment Number 4 to Executive Employment Agreement with Menderes Akdag (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed January 28, 2013).
(14) Corporate Code of Ethics
 14.1Corporate Code of Ethics (incorporated by reference to our definitive Proxy Statement for our 2004 Annual Meeting of Stockholders filed June 30, 2004).
(21) Subsidiaries of Registrant
(21) Subsidiaries of Registrant
 21.1Subsidiaries of Registrant*
(31) Certifications
(31) Certifications
 31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).*
 31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).*
 (32)Certifications
 32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 1350.**
 

*Filed herewith
**Furnished herewith
 
46

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: May 29, 2012
  PETMED EXPRESS, INC.
  (the “registrant”)
  
Dated: May 27, 2014
PETMED EXPRESS, INC.
(the “registrant”)
By:  /s//s/ Menderes Akdag 
 
  Menderes Akdag
  Chief Executive Officer and President
  (principal executive officer)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities on May 29, 2012.27, 2014.
 
SIGNATURE TITLE
   
 
/s/ Menderes Akdag
 
Chief Executive Officer and President
(principal executive officer)
Menderes Akdag Officer and Director
   
/s/ Robert C. Schweitzer Chairman of the Board
Robert C. Schweitzer Director
   
/s/ Bruce S. Rosenbloom 
Chief Financial Officer and Treasurer
(principal financial and accounting officer)
Bruce S. Rosenbloom Officer
   
/s/ Ronald J. Korn Director
Ronald J. Korn  
   
/s/ Gian M. Fulgoni Director
Gian M. Fulgoni  
   
/s/ Frank J. Formica Director
Frank J. Formica  
 
47
44